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Abstract

DEVELOPMENT OF MECHANICAL CARDIOVASCULAR ASSIST DEVICES FOR
FONTAN PATIENTS: TWO NOVEL APPROACHES
By Sonya Sanat Bhavsar, B.S.
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Mechanical Engineering at Virginia Commonwealth University.

Virginia Commonwealth University, 2010

Major Director: Dr. Amy L. Throckmorton
Assistant Professor, Department of Mechanical Engineering

Few therapeutic alternatives exist for patients with a failing single ventricle
physiology. To address this need, this thesis project investigated two new therapeutic
alternatives, which sought to positively augment the Fontan hemodynamics. The first
modality introduced a non-invasive method of external pressure application to the lower
extremities. A clinical study (n=2) was conducted, and results indicated an increase in flow
as a consequence to an increase in transmural pressure in the lower extremities. The second
modality investigated a minimally invasive blood pump. Numerical analyses of the pump
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xiii
were performed to examine hydraulic performance under physiologic conditions. The
pump produced pressure rises of 1 to 25 mmHg over flows of 1 to 4 LPM, has a blood
damage index less than 1% and was also found to successfully augment the hydraulic
energy of the Fontan physiology. This work resulted in substantial progress to develop
both modalities and address a significant human health problem. This document was
created using Mircosoft Word 2007.

CHAPTER 1 MOTIVATION AND SIGNIFICANCE
1.1 Congenital Heart Defects and Diseases
Congenital heart defects are abnormalities with the heart’s structure present at the time
of birth caused by the incomplete or abnormal development of fetal heart during pregnancy
[1, 2]. These structural defects involve the interior walls of the heart, heart valves, and
arteries and veins providing blood perfusion to cardiac tissue. The irregular cardiac
structure deflects normal blood flow through the heart causing flow to slow down, proceed
in the incorrect direction or location, or be completely blocked. The severity of defects can
range from minimal requiring little to no corrective treatment to complex with life
threatening symptoms requiring medical and surgical intervention and eventually a heart
transplant [3, 4].
Congenital heart defects are the most common type of birth defect. According to the
2006 March of Dimes study, each year approximately 8 million children are born
worldwide with serious, life-threatening heart defects which necessitate corrective surgery
[5]. The United States alone accounts for about 1 million of these children born with
congenital heart defects with 40,000 requiring immediate surgical intervention [5,6].
Specific conditions include:
1. Septal Defects – holes in the wall which separates the left side of the heart from the
right side of the heart allowing mixing of oxygenated and deoxygenated blood.
1

2
Septal defects can occur in the atria as atrial septal defects (ASD) or in the ventricle
as ventricular sepatal defects (VSD). In general, a VSD is more severe and can
require surgical intervention dependent on the magnitude of the defect [6-8].
2. Valve Defects – structural abnormalities of valves which control blood flow
throughout the heart and to the body and lungs. Valve defects include (a) stenosis,
thickening of valve flaps preventing the valve from fully opening, (b) atresia,
atypical formation of the valve lacking a passage for blood flow, and (c)
regurgitation, incomplete closure of the valve causing retrograde backflow of
blood. Common examples of valve defects include aortic stenosis, pulmonary
stenosis, pulmonary atresia, and tricuspid atresia [6, 8].
3. Coarctation of the Aorta (COA) – narrowing of a region within the aorta resulting
in a significant decrease of blood flow to the lower body [6, 7].
4. Hypoplastic Left Heart Syndrome - underdeveloped structures of the left, or
systemic side of the heart causing life threatening inadequate blood flow to the
body. Within the first few days of the life the baby is diagnosed critically ill and
requires immediate surgical intervention [2, 6, 7]
5. Patent Ductus Arteriosus (PDA) – incomplete or no closure of the ductus arteriosus
(DA) blood vessel which shunts blood away from the lungs redirecting to the body.
The condition causes excessive blood flow to the newborn’s lungs. PDA commonly
occurs in premature births [6-8]
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6. Tetralogy of Fallot (TOF) – complex defect resulting from a combination of four
heart defects: pulmonary stenosis, VSD, right ventricular hypertrophy, and aortic
dysfunction receiving blood from both left and right ventricles [6].
7. Transposition of the Great Arteries – transposition of the pulmonary artery and
aorta resulting in delivery of deoxygenated blood from the right ventricle to the
body and redelivery of oxygenated blood to the lungs from the left ventricle [6, 8]

The most serious and life threatening congenital heart defects are those which involve
multiple and significant malformations of the heart chambers and vasculature.
Cardiovascular malformations attribute to 6-10% of all infant deaths [1, 2]. These defects
represent one of the two leading causes of neonatal death and have an occurrence of
approximately 1- 8 in 1000 live births with incidence of 1 in 6 infants born preterm [2].
Cardiovascular malformations have also been found to contribute to sudden infant death.
Conditions such as tricuspid artresia and hypoplastic left heart syndrome prompt single
ventricle anomalies, or the contingency of only one functional ventricle. The only chance
of survival for these patients is a staged surgical palliation commonly known as Fontan
completion [4, 9].

1.2 Fontan Physiology
Clinical interventions prior to the Fontan operative procedure involved aortopulmonary
shunts and pulmonary artery bands, designed to moderate hypoxemia and congestive heart
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failure. These interventions, however, cause volume and pressure overloads, often leading
to chronic ventricular hypertrophy and subendocardial ischemia [10].
Repair of univentricular physiologies through the Fontan conversion is a staged
surgical palliation procedure. The first stage, known as the Norwood, occurs within the
first two weeks of life and provides blood flow to the lungs through a pulmonary arterial
shunt [11]. Figure 1 illustrates the Norwood repair.

Figure 1: Norwood surgical intervention for
single ventricle physiologies. A shunt is placed
between aorta and pulmonary arteries to reduce
blood oxygen desaturation and promote development
of the pulmonary vasculature.

Once the risk of elevated pulmonary vascular resistance in the pulmonary beds has
decreased the second stage, known as the Glenn, disconnects the Norwood shunt and
directly connects the superior vena cava (SVC) to pulmonary circulation.

Figure 2: Glenn surgical palliative procedure
providing a direct connection from the superior
vena cava to pulmonary circulation. The second
staged surgical palliation, referred to as the Glenn
procedure, often performed after six weeks and
directly connects the SVC to the pulmonary
arteries.
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The Glenn procedure usually occurs six weeks after birth, followed by the Fontan
conversion which usually occurs between the ages of 3-5 years, although each patient is
unique and surgical teams complete the third stage on a case by case basis. Figure 2 shows
the Glenn surgical configuration. Surgeons may decide, based on the patient’s
hemodynamics and body response, to remain at the Norwood, Glenn, or Hemi-Fontan
stage for several years.

Figure 3: Variations of the Fontan surgical palliation procedure. (A) Intra-Atrial
Fontan (B) Lateral Tunnel TCPC (C) Extra-Cardiac TCPC[12]

The success rate of these high risk procedures is less than 75% [11]. Each patient
presents a unique challenge to surgical teams resulting in numerous modifications of these
palliative procedures such as the Hemi-Fontan, Intra-Atrial Fontan, and Extracardiac
Fontan as a few are demonstrated in Figure 3. The total cavopulmonary connection
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(TCPC) is an example of the extracardiac Fontan first described by de Leval et al [13].
This procedure connects the inferior vena cava (IVC) and superior vena cava (SVC)
directly to the unbranched right pulmonary artery [10, 14]. TCPC creates a new “manmade” physiology which entails systemic venous return transmitted directly to pulmonary
circulation, formulating minimal pulsaltility of flow in pulmonary arteries [10, 15-17].
Thus, Fontan circulation is characterized by the absence of a pulmonary ventricle which is
responsible for driving flow to the lungs.
Postoperative, these patients suffer from a number of associated complications due to
their “man-made” physiology. Of those who survive the three staged palliation, only 85%
survive the first month, 81% the first year, 79% the first five years, and 71% after 10 years
[17]. Among the prevalent pathologies an increased after-load on the great veins due to
elevated pulmonary pressures not only results in a significant reduction of preload reserve,
but also leads to chronic conditions such as congestive heart failure and diminished
exercise capacity. Decreased venous return, supraventricular arrhythmias, protein losing
enteropathy, and aortopullmonary collateral vessels also plague the life-long Fontan
patients [10, 15, 16, 18].
Due to the TCPC, the Fontan patient’s pulmonary perfusion is reliant upon IVC
pressure, thus systemic pressures are elevated to provide flow. As described by West et al.
[19] in 1964, the upright lung is classically divided into three regions of characteristic
alveolar pressure zones secondary to gravitational forces. Each zone is described by
comparison to arterial and venous pressures. The superior zone demonstrates alveolar
pressures greater than both arterial and venous pressures, the middle zone with alveolar
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pressures less than arterial yet greater than venous pressure, and zone 3 with alveolar
pressure less than both arterial and venous pressure. As can be assumed, zone 3 facilitates
maximal pulmonary perfusion. Considering their decreased pulmonary vascular
capacitance and correlated elevated pulmonary vascular resistance, it is likely that Fontan
patients have a reduced zone 3.
A recent study performed by Lamour et al. [20] assessed the long term effects of age,
diagnosis, and previous surgery in both adult and pediatric patients who underwent heart
transplant for congenital heart disease (CHD). The multi-institutional study merged the
registries from the Pediatric Heart Transplant Study (PHTS) and Cardiac Transplant
Research Database (CTRD) to generate a combined dataset of patients receiving a heart
transplant secondary to CHD. CTRD collected information from patients >18 years of age
at the time of transplant and PHTS collected from those <18 years of age. Of the 488 CHD
patients (121 from CTRD and 367 from PHTS) the last major surgical operation performed
prior to transplant was the Fontan in 22% of patients and Norwood or variants of the Glenn
in 21% of patients. Post transplant, patients with a previous Fontan had an 8.6-fold
increase risk of death as compared to all other CHD patients. The survival rates in Fontan
patients was 71% after the first year and 60% five years post transplant [20].

1.3 Pediatric Mechanical Circulatory Support
Improved management strategies could reduce the risk of developing late stage, or
chronic, Fontan induced pathologies [4, 17, 18, 21, 22]. Current research indicates that by
improving ventricular-vascular interactions, after-load reducing agents can improve Fontan
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hemodynamics [23-26]. Several surgical interventions have been introduced to improve the
quality of life, increase the time to full cardiac transplant, and raise the overall odds of
survival [17, 21, 27]. Mechanical circulatory support devices have become an increasingly
popular treatment option for single ventricular assistance. Historically, preference was
placed on extracorporeal membrane oxygenation (ECMO) as the fundamental form of
mechanical circulation in pediatrics. However, efforts have been made towards the use of
ventricular assist devices (VADs) to extend the time to Fontan failure necessitating full
cardiac transplantation. Statistically, VADs have been reported as improving the hospital
survival rate to 89% [9, 27, 28]. Surgical re-interventions to mediate failing Fontans
include interjection of baffle fenstrations, atrioventricular valve repairs, hepatic vein
reinclusions, pacemaker placement, prior to full heart transplantation [21]. The incidence
for ultimate full cardiac transplantation is high, though the waiting time for a donor organ
can be extensive and the resulting operative mortality rate of 44% [21]. Mechanical
circulatory support is critical as a bridge-to-transplant, increasing the likelihood of survival
while waiting for a donor heart.

1.3.1

Extracorporeal Membrane Oxygenation (ECMO)

Extracorporeal membrane oxygenation (ECMO) is the most common resource utilized
for newborn and pediatric cardiopulmonary support for patients with low refractory cardiac
output, arrhythmias, cardiac arrest, persistent hypoxemia or inadequate detachment from
cardiopulmonary bypass [29-33]. Primary use of ECMO is to temporarily replace lung
function, heat function, or both allowing recovery of a patient’s cardiopulmonary system
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from an acute reversible insult or injury. Numerous studies and patient reports have been
published reporting the successful use of ECMO as a bridge-to-transplant and bridge-tosurgical intervention in addition to recovery [27, 30, 34, 35]. The first successful use of
ECMO for cardio pulmonary bypass was reported in 1975. Since this time, the
Extracorporeal Life Support Organization, a coalition founded in 1989 to study the clinical
use of ECMO, has maintained a registry of more than 30,000 patients, a majority of which
were neonates presenting with respiratory failure [36, 37] . Neonates and newborns present
with much higher survival rates as compared to pediatric and adult patients. This is
attributed to the reversibility of the disease and absence of chronic lung and heart
conditions [38, 39].
ECMO systems are complex and integrate several mechanical components [28, 39]. A
sample ECMO circuit from researchers at the Congenital Heart Institute of Florida [35] is
illustrated in Figure 4. System components include a roller pump, ECMO bladder, silicone
membrane or hollow fiber oxygenator, heat exchanger, a centrifugal or roller pump, and IV
pumps for ultrafiltrate and replacement fluid.
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Figure 4: Schematic of a typical ECMO loop. ECMO provides hemodynamic and
pulmonary support.[35]

The accumulation of numerous instruments leads the way to several possible complications
and creates challenges for patients and hospital staff. An air embolism may form and could
enter the arterial blood causing systemic embolization. Bubble detectors integrated into the
system provide early warnings and allow hospital staff to bridge bubbles to the bladder for
aspiration. Clot formations and plasma protein buildup can occur in the oxygenator
membrane reducing the surface contact area for blood and gas. Additional technical
failures include oxygenator failure, failure of heat exchanger, pump failure, and tube
rupture [34, 35, 40].
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Heparin must be continuously infused to maintain ACT between 180 to 220 seconds
with calcium added to reverse CPD-A anticoagulation effects [30]. Heparin excretion is
part metabolized and part intact in urine, therefore urine production has a considerable
effect on apparent heparin utilization rate. The half-life of heparin in neonates on ECMO is
45 to 70 minutes. Heparin levels must be checked every morning by performing a heparin
assay. Side effects from heparin include intracranial bleeding and bleeding at the cannula
site [30, 41, 42].
Patients on ECMO are immobile and must remain under supervision due to the
bulky complex system and propensity of complications. Average time for extubation is 24
to 48 hours and supplemental oxygen is required for the first week [40, 43, 44]. Though
the oxygenator, coating material of the circuit internal surface, and blood flow controller in
ECMO systems have been refined and modernized since the systems first introduction in
the late 1970s, survival rates post hospital discharge in pediatric patients is approximately
50% [30, 35, 45-47] . Single ventricle physiologies have been hypothesized as one cause
for high mortality rates [30, 34].

1.3.2

Ventricular Assist Devices (VADs)
While many heart pumps or ventricular assist devices (VADs) are being developed

and in various stages of clinical testing, all of these blood pumps generate pressures in far
excess of the desired range for cavopulmonary support. Progress in the development of
pediatric VADs has achieved new milestones and continues to quickly evolve; a majority
of these more compact, pediatric VADs, however, have been designed to support the
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systemic circulation in a normal biventricular physiology, not to support a cavopulmonary
circulation [21, 36, 48]. All of these mechanical blood pumps were designed and
developed for adult or pediatric patients with congestive heart failure (CHF) and to support
the systemic circulation, not the unique anatomic physiology of the cavopulmonary
connection [26]. These devices produce pressures that exceed the desired range to be used
for cavopulmonary support. Researchers theorize that a pressure boost of only 2 to 5
mmHg may be sufficient to unload the cavopulmonary circulation in adolescent and adult
patients who have a failing single ventricle [49]. The rising need for alternative therapeutic
options for Fontan patients created the motivation for the development of an intravascular
cavopulmonary assist device.

1.3.3

Cavopulmonary Assist Devices
Several institutions have begun to pursue research and development of

cavopulmonary assist devices. Rodefeld and colleagues [22] have successfully
demonstrated the use of the axial flow Hemopump to assist cavopulmonary flow in
animals. This research group is also developing an innovative percutaneously-implantable,
expandable propeller blood pump as a cavopulmonary assist device [22]. Limitations of
this design include a wide distance between the rotor and blade-tip, increasing shear
stresses, and an extremely short contact time with the thin propeller blades, preventing
flow control downstream. Riemer et al. [50] at the Stanford University have used a sheep
model of the total cavopulmonary connection to test the response to the Thoratec
HeartMate II axial flow blood pump (Thoratec Corporation, Pleasanton, CA). These
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studies demonstrated a baseline return of cardiac output, inferior vena caval flow, and
arterial pressures. Similarly, the research team at the University of Colorado has made
steady progress through numerical and in vitro studies on the development of an axial flow
pump for proposed use in the IVC only [26].
The Division of Cardiac Surgery and Department of Pediatrics at the University of
Maryland Medical Center in Baltimore, MD recently published a case study on the use of
the Berlin Heart for the failing Fontan, providing more evidence for the continued
research and development of a VAD for single ventricle physiologies [51]. An 18-month
old patient was placed on cardiac support for 179 days, at which time the VAD was
removed to optimize her general status. The patient expired 55 days post-VAD removal; a
dislodged tracheostomy tube was claimed the probable cause of death.
Another recent case study was performed by the Department of Cardiopulmonary
Transplantation at the Texas Heart Institute at St. Luke’s Episcopal Hospital involving a
14-year old male Fontan patient implanted with a left ventricular assist device as BBT. The
HeartMate implantable pneumatic left ventricular assist system (IP LVAS) was implanted
after the patient was placed on cardiopulmonary bypass during the operative procedure.
The HeartMate IP LVAS proved full circulatory support for 45 days at which point a donor
heart was available and implanted. The cardiac transplantation was a success, and the
patient has remained health for more than 2 years post-transplant [52].
As proven by these research and clinical teams, the standard axial flow pump
design has suitable characteristics for cavopulmonary assist. The aforementioned blood
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pump designs, however, may be obstructive to flow in the event of rotational failure, and
implantation requires invasive surgery.

1.4 Noninvasive Counterpulsation and Minimally-Invasive Intravascular Assist
In further support of this effort to develop alternative therapeutic options for Fontan
patients, we are developing two modalities as a bridge-to-transplant, bridge-tohemodynamic stability, bridge-to-surgical reconstruction or long-term support alternative
for these patients. The first modality is an external counterpulsation system as a long-term
clinical management strategy. This technology involves using commercially-available,
medical anti-shock trousers on single ventricle patients. The inflation and deflation of these
trousers applies circumferential pressure to the lower extremities which translates into an
increase in venous return pressure and cardiac output. We speculate that this
counterpulsation system will improve functional and exercise capacity in these patients.
The second modality is a collapsible, percutaneously-placed, axial flow blood
pump to support the cavopulmonary circulation. Mechanical pressure augmentation of
blood flow in the cavopulmonary circulation would decrease elevated systemic venous
pressure and increase ventricular preload. This type of blood pump, which is specifically
designed to support the unique anatomic and physiologic conditions of the univentricular
circulation, has never been developed.
The intravascular, axial flow blood pump with a magnetically levitated rotor and a
uniquely shaped protective cage. Figure 5 illustrates the conceptual design of the blood
pump. The intravascular axial flow pump is designed for percutaneous positioning in the
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inferior vena cava (IVC). The outer protective cage has radially arranged filaments that
serve as touchdown surfaces to protect the vessel wall from the rotating components. Each
filament is hydrodynamically designed to reduce drag and to maximize energy production
from the rotating, engineered impeller blades. Currently the rotating pump consists of an
impeller with four uniquely designed and helically wrapped blades to maximize energy
transfer. Pump rotation is induced through a motor-magnetic bearing suspension, which
levitate and rotate the impeller within the protective cage of filaments. An outlet nose is
also located at the outflow of the pump to physically limit the axial movement of the
impeller, to connect the cage filaments, and to house bearings which support the impeller
during operation. The blade tip-to-tip diameter of the first generation design is 14 mm in
the fully open configuration. In this study, for the purposes of measuring hydraulic
performance, the pump prototype was mounted to a drive-shaft that was supported by
mechanical bearings. The target design for the intravascular pump is to generate flow rates
of 0.5 to 4 L/min with pressure rises of 2 to 25 mmHg for rotational speeds of 3000 to 6000
RPM.
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Figure 5: Conceptual Design of the Axial Flow Blood Pump. (A) The device consists
of a protective sheath with cage filaments, a rotating shaft and catheter, an impeller blades,
diffuser region, and inlet and outlet sections. (B) Position of the cavopulmonary assist
device in the IVC of the TCPC for Fontan patients. It is designed to augment pressure and
thus flow in IVC and subsequently drive blood into the left and right pulmonary arteries
(LPA and RPA) while supporting the incoming flow from the superior vena cava (SVC).

1.5 Project Goal and Objectives
The goals of research for this M.S. thesis included the design, development, and
evaluation of two modalities augment Fontan circulatory hemodynamics and cardiac
function. A dual methodical approach to improving Fontan function was determined by the
need for both preventative hemodynamic assistance and mechanical assistance to provide a
bridge-to-transplant, bridge-to-surgical reconstruction, or bridge-to-recovery. The
following are the objectives of this research:
1. Obtain a thorough understanding of the unique anatomy and physiology of the Fontan
surgical intervention and circulatory impact
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2. Determine the parameters and engineering design specifications for circulatory
augmentation of Fontan hemodynamics.
3. Design and retrofit adult and pediatric size external pressure garment for a noninvasive,
preventative approach for hemodynamic support for Fontan patients.
4. Contrive and compose pressure garment protocols and obtain IRB approval for MAST
clinical trials.
5. Conduct MAST clinical trials on two patients during cardiac catheterizations at the
Medical College of Virginia.
6. Design and conduct numerical analyses on an intravascular, axial flow blood pump for
minimally invasive mechanical circulatory support for Failing Fontan physiology
to serve as a bridge-to-transplant, bridge-to-surgical intervention, or bridge-torecovery.
7. Generate computational models for the total cavopulmonary connection (TCPC)
Fontan including idealized configurations and patient specific configurations
derived from MRI images.
8. Conduct computational fluid dynamics (CFD) analyses on TCPC models with
intravascular blood pump mechanical support.
9. Perform the following analyses: pressure-flow, blood damage, shear stress, quasisteady state, and energy loss calculations.
This thesis project provided insights into two forms of therapeutic treatments for Fontan
patients. Achievement of these objectives resulted in substantial progress in the
development of both modalities to address a significant human health problem.
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1.6 Thesis Outline
This thesis reports two methods of circulatory augmentation for Fontan patients.
The design and development of two mechanical modalities is detailed in subsequent
chapters. Chapter 2 reports the construction of a noninvasive mechanical circulatory
augmentation garment designed improve hemodynamics by reducing the workload of the
systemic ventricle and providing increased pressure and blood flow to the lungs. The goal
of the external circulatory augmentation garment is to provide patients with a therapeutic
medical device for use at home to alleviate some cardiac workload thus providing a
preventative approach to combat the ensuing Failing Fontan physiology.
Chapter 3 reports the design and development of an intravascular, axial flow blood
pump intended as a minimally invasive approach for mechanical circulatory augmentation
of the Failing Fontan physiology. Computational fluid dynamic (CFD) analyses were
performed with the pump placed in idealized and patient specific TCPC models. The
results from both the counterpulsation studies and numerical simulations are reported in
Chapter 4. Chapter 5 discusses the success and usefulness of both devices and indications
for clinical use. Conclusions and future research expectations and goals are detailed in
Chapter 6.

CHAPTER 2 METHODS AND MATERIALS:
COUNTERPULSATION
2.1 Theory of External Circulatory Augmentation
Traditionally mechanical cardiovascular assist devices are invasive and designed
specifically for adult patients suffering from congestive heart failure. The success of these
devices in adults with CHF is well reported and discussed in earlier sections. Though these
traditional mechanical circulatory support devices have been shown to mediate the failing
Fontan physiology prior to full transplant, current research indicates device success as only
a short term bridge to transplant, not for use over an extensive period of time [21, 23, 27,
48]. Additionally, these devices require an invasive procedure for implementation and no
clinically available device to date has been designed to specifically augment the unique
circulatory demands of a Fontan.
The theory of external circulatory augmentation can be contrived from studying
skeletal musculature during exercise. The extension and contraction of skeletal muscle
during exercise is shown to augment blood flow through a pumping action generated by
the propulsion of blood forward upon muscular contraction. By applying external pressure
to the extremities it is possible to mimic this pumping action.
In an attempt to achieve the goals of mechanical circulatory assistance while
reducing the surgical risk and cost to patients, we venture to apply external pressure to the
19
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lower limbs as a preventative measure and long-term clinical treatment for Fontan patients.
In the future we plan to employ external pressure to the lower limbs from a novel medical
device designed to augment venous return for patient use at home. This device will assist
patients through the augmentation of systemic blood flow to the pulmonary arteries, thus
reducing ventricular workload, increasing venous return and pulmonary perfusion, and
reducing cardiac afterload. Our review of literature and preliminary studies provide a
proof-of-concept [53-56]. Two available technologies fit the criteria for obtaining relevant
data for our intended contrivance: clinical application of Medical Anti-Shock Trousers
(MAS trousers) and enhanced external counterpulsation (EECP).

2.2 Historical Predecessors
2.2.1 Military/Medical Anti-Shock Trousers
The origin of MAS trousers dates back to 1903, when the developer, George Crile,
discovered the concept of counterpressure for treatment of hypotension associated with
surgical procedures [57]. Crile developed and constructed the first counterpressure medical
device as a pneumatic double layered rubber suit designed exerted uniform pressure upon
inflation. Since Crile’s time, MAS trousers have been updated and are part of protocol for
every ambulance to use in situations of urgent assistance to patients suffering hypovolemic
shock [58]. MAS trousers apply a fixed external pressure through pneumatic means to
maintain a systolic pressure of 100 mmHg through increasing impedance of blood flow to
the lower extremeties.
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2.2.2 Enhanced External Counterpulsation
In contrast to MAS trousers, enhanced external counterpulsation (EECP) is a noninvasive counterpulsation technique designed as a therapeutic alternative for adult patients
suffering from ischemic heart diseases. Approved by the Food and Drug Administration
(FDA) in 1995, EECP has been demonstrated as safe and effective in the treatment of
angina. A Multicenter Study conducted by Werner et al. of more than 5000 patients from
over 100 centers concluded that EECP decreases angina episodes and extends the time to
an exercise-induced angina episode [56].
EECP is an electrocardiogram-triggered inflation and deflation of pressure cuffs
wrapped around a patient’s lower extremities. The cuffs are inflated and deflated
sequentially and circumferentially, resulting in the propulsion of retrograde blood flow
through the arteries thus increasing coronary perfusion during diastole (ventricular filling).
Figure 6 illustrates the inflation-deflation pattern timed with the cardiac cycle.
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Figure 6: Electrocardiogram-trigged EECP. External pressure applied to the lower
limbs is triggered by the cardiac cycle. Diastolic inflation promotes retrograde flow to the
coronary arteries[59].
In 2002, Ma et al. [53] performed a clinical trial on 10 pediatric patients to assess the
usefulness of using external counterpulsation early postoperatively after the Fontan
conversion at the Childern’s Medical Center in Dallas, TX. The study focused on the
benefits of counterpulsation when applied to patients immediately postoperative for 10
minutes. Though the authors state success with safe application to pediatric patients and an
increased in cardiac index, no further trials were published.

2.2.3 Application of Pulsation Technology to Fontan Patients
Due to the extensive demonstration of success in adult CHF patients, it is expected that
EECP or a similar technology (i.e. retrofitted MAS trouser configuration) would have
superior results on pediatric CHD patients. This assumption is based on the symptomatic
and physiological similarities between these two categorical patients. Their pathological
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conditions arise from the common source of poor myocardial functionality.
Counterpulsation therapy delivered with cardiac synchronization has consistently
demonstrated immediate improvement in exercise tolerance, myocardial perfusion, venous
return, and cardiac output, with several long-term benefits such as improved endothelial
function, increased peripheral oxygen uptake, and augmented ventricular systolic and
diastolic function [54, 56]. By focusing on the benefits derived from pulsation in
conjunction with simplification of the device, it is possible to develop a noninvasive,
external pulsation device for at home therapeutic use without the need for outpatient
expenditures.
Therefore, we executed a clinical study using commercially available MAS trousers on
Fontan patients. We hypothesized that routinely administered, non-invasive, external
counterpulsation will: 1) enhance flow from the great veins through the lungs, and 2) will
improve functional and exercise capacity in these patients with single ventricle physiology.
We propose to initially evaluate this hypothesis by performing a feasibility study on
pediatric patients and young adults (ages of 10 to 45) with congenital heart disease. This
study measured the increase in venous pressures and cardiac output with circumferentially
applied, external pressures on the lower extremities using commercially available medical
anti-shock trousers. Figure 7 below illustrates the location of external pressure application
via MAS trousers.
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Figure 7: External pressure application to lower limbs and abdomen using MAS
trousers. Hypothesized forward propulsion of blood, illustrated as a bolus in the mid-thigh
above, due to external pressure to augment Fontan circulatory hemodynamic.

2.3 New Pulsation Device
Two sets of MAS trousers (David Clark Company Incorporated, Worcester, MA, U.S.
Patent No. 3933150) were procured and retrofitted for the counterpulsation studies: an
adult size and a pediatric size. The adult and pediatric size differed in length of lower
extremity cuffs, width of the abdominal cuff, and circumferential length of the abdominal
cuff. The pressure compartments on these MAS trousers were individual such that the
abdominal sections were interchangeable as well as the lower extremity sections. This
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provided allowance for some degree of personalized fit for the patients involved in the
study. For example a tall slender subject could use the adult size lower extremity sections
in conjunction with the pediatric size abdominal section.
System pressure application was provided via two means of airflow, coarse and fine
adjustments, laid in series to the pressure garment. Bulk airflow to generate pressures
accurate within approximately 10 mmHg originated from a standard air pump (Intertek
Listed, Model: HB-505B). The air pump provided the coarse pressure adjustment to
quickly elevate the pant pressure application to the patient to the desired level. A hand
pump found on most sphygmomanometers was utilized for fine adjustments, elevating and
relieving pressures within approximately 1 mmHg accuracy. In conjunction, the coarse and
fine pressure applicators were capable of providing the external pressure application for the
clinical trials.
The pressure gage was added to the system in parallel to airflow through the trousers
compartments, downstream of the pump and upstream of the patient. A standard dial
pressure gage found on most sphygmomanometers was used to detect and approximate
trouser pressure. Figure 8 below demonstrates the design and layout of the retrofitted
MAS-trousers.
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Figure 8: Schematic of retrofitted MAS trousers used for counterpulsation clinical
trials.

2.4 Clinical Study
VCU Investigational Review Board (IRB) approval was obtained for this study (HM
#11906). The study population consisted of volunteer subjects aged 10 to 45 years who are
recruited by staff and participating personnel. All subjects had a previously scheduled,
dual-sided, cardiac catheterization. To-date, two subjects have been recruited.
The subjects were examined prior to enrollment. The exclusion criteria are as follows:
recent surgery or Fontan conversion within one year or less, cognitive impairment,
uncontrolled arrhythmias, history of pulmonary embolism or deep vein thrombosis,
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uncontrolled hypertension, uncontrolled congestive heart failure, clinically significant
valvular disease (e.g. aortic regurgitation), acute myocardial infarction, excessive
tachycardia or marked bradycardia, bleeding diathesis, absent pedal pulses, lower
extremity and pulmonary edema, aortic aneurysm, and diaphragmatic hernia [54]. Table 1
summarizes these exclusion criteria. Neither of the participating subjects met any of these
criteria.
Table 1: Exclusion Criteria for clinical trial.
Exclusion Criteria
1. Uncontrolled Arrhythmias
2. Nonsustained ventricular tachycardia (NSVT)
3. Recent Pulmonary Edema
4. Recent prognosis of Deep Vein Thrombosis
5. Uncontrolled Hypertension
6. Abdominal Aortic Aneurysm > 4.0 cm
7. Uncontrolled Congenital Heart Failure
8. Acute Myocardial Infarction
9. Aortic Insufficiency
10. Mitral or Aortic Stenosis
11. Excessive Tachycardia
12. Marked Bradycardia
13. Bleeding Diathesis
14. Symptomatic peripheral vascular disease
15. Unsuitable deformity in lower extremity anatomy

After obtaining informed consent, the patient was prepped for the previously scheduled
cardiac catheterization. The subjects were placed in the supine position with the MAST
garment applied but not inflated. A blood pressure cuff was wrapped around the patient’s
arm for routine measurements; a pulse oximeter was placed on the patient’s index finger to
measure oxygen saturation and heart rate during the study. Standard electrocardiogram
leads were also appropriately located. A catheter was then inserted into the femoral vein
and/or artery after the site had been cleansed and numbed with a local anesthetic, and
according to the VCU standard protocol for cardiac catheterization.
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Baseline measurements of blood pressure, cardiac output, respirations, right atrial
pressure / central venous pressure, and pulmonary capillary wedge pressure, O2 sat, and
heart rate were taken. Based on the patient’s diastolic pressure, we determined three
separate pressure intervals to evaluate, up to 20 mmHg above their diastolic pressure.
After a first set of vital signs were obtained, the first pressure level was administered.
The MAS trousers were inflated and a circumferential pressure was applied to the lower
extremities similar to a blood pressure cuff. This pressure was held for 20 to 40 seconds
and then released for 10 seconds. The pressure was applied again. These intermittently
applied pressures at the first interval occurred for 3 to 5 minutes. Clinical measurements
were ongoing.
At the conclusion of this 3 to 5 minute first test period, the patient’s vital signs
were reassessed and the MAS trousers were deflated. The patient rested for 3-5 minutes.
Then, the second pressure level was tested, which is slightly higher than the first interval.
The MAS trousers were inflated and a circumferential pressure was applied to the lower
extremities. This second interval pressure was held for 20 to 40 seconds and then released
for 10 seconds. The pressure was then applied again. These intermittently applied
pressures at the second interval occurred for 3 to 5 minutes. Clinical measurements were
ongoing.
At the conclusion of this 3 to 5 minute second test period, the patient’s vital signs were
again reassessed and the MAS trousers were deflated. The patient rested for 3-5 minutes.
Finally, the third and last pressure level was evaluated. This third interval pressure was
held for 20 to 40 seconds and then released for 10 seconds. The pressure was then applied
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again. These intermittently applied pressures at the third interval occurred for 3 to 5
minutes. Clinical measurements of aortic systolic and diastolic pressures, pulmonary
pressures, and TCPC pressure were ongoing. Upon completion, a final set of vital signs
was reassessed and the MAS trousers were deflated. The patient was able to rest for 3 to 5
minutes. After 5 minutes, a final set of baseline vitals was obtained.
Deflation of the anti-shock trousers was carefully completed in order to maintain
cardiac stabilization. We ensured that the subjects were not exhibiting any signs of shock
and that they had a stable, strong, and regular heart rate, respirations, and blood pressure.
Vital signs were carefully monitored during the deflation process.
All measurements were recorded in manner that is in compliance with IRB rules
and HIPPA regulations. The subsequent table is a sample spreadsheet as indicative of the
data recorded for each study.
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Table 2: Sample data spreadsheet for clinical trials.
Study Number:

Recording
1
2
3
4
5

Age/Sex

Time

BP

HR

Diagnosis
Baseline Measurements
Resp.
O2 sat.
Left atrial / CVP

Pulmon. Cap. Wedge

Applied External Pressure of _________
Time

BP

HR

Time

BP

Time

Time

Resp.

O2 sat.

Left atrial / CVP

Pulmon. Cap. Wedge

HR

Applied External Pressure of _________
Resp.
O2 sat.
Left atrial / CVP

Pulmon. Cap. Wedge

BP

HR

Applied External Pressure of _________
Resp.
O2 sat.
Left atrial / CVP

Pulmon. Cap. Wedge

BP

HR

Baseline Measurements
Resp.
O2 sat.
Left atrial / CVP

Pulmon. Cap. Wedge

1
2
3
4
5

1
2
3
4
5

1
2
3
4
5
Recording
1
2
3
4
5

2.5 Chapter Summary
Counterpulsation has been shown to improve cardiovascular hemodynamics and
provide symptomatic relief in adult patients suffering from CHF. Inferring from the
similarities in symptoms between adult CHF patients and patients with failing Fontan
physiology it was hypothesized that external pressure augmentation to the lower limbs of
Fontan patients would provide them hemodynamic relief and reduce cardiac workload. An
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IRB approved study was conducted over the course of Fall 2008 to Spring 2010. The
clinical trial was conducted during prescheduled cardiac catheterizations and employed
retro-fitted MAS trousers. Two patients were recruited and results from the clinical trials
are provided in Chapter 4.
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CHAPTER 3 METHODS AND MATERIALS: INTRAVASCULAR
BLOOD PUMP
In contrast to the completely non-invasive and external pulsation device, another
approach to augment pressure in the total cavopulmonary connection (TCPC) of Fontan
patients involves the use of an intravascular blood pump. This thesis evaluated the use of
such a pump in the inferior vena cava (IVC) through numerical means. The cavopulmonary
assist device represents a minimally-invasive technique to support Fontan patients in the
cardiac catheterization lab.
As discussed in previous chapters, repair of univentricular physiologies through the
operative Fontan procedure manifests a new, “man-made” circulatory pattern for these
patients deriving from a direct connection of the great veins to the pulmonary arteries. In
recent years, progress in surgical advances of the TCPC has reached a plateau. Therefore, a
rising interest in the implementation of an intravascular blood pump in the IVC has
emerged.
Normal cardiac anatomy utilizes the right ventricle as a pumping chamber to propel
blood forward into pulmonary circulation. Due to their univentricular physiology, Fontan
patients have passive blood flow to the lungs. The use of an axial flow blood pump in the
IVC would compensate for the loss of energy from the univentricular physiology and serve
to recoup and maintain hemodynamic stability for patients suffering from a failing Fontan.
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3.1 Conceptual Pump Design
In order to produce a more effective and minimally invasive bridge-to-transplant,
bridge-to-recovery, or bridge-to-surgical reconstruction, we have developed a collapsible,
percutaneously inserted, magnetically levitated axial flow blood pump to support the total
cavopulmonary connection (TCPC) of a failing Fontan in adolescent and adult patients.
Our intravascular pump would provide mechanical augmentation of blood flow from the
inferior vena cava to the lungs, thus enhancing cardiovascular hemodynamics through
improved systemic pressure, increased ventricular filling, and augmented cardiac output.
The axial flow blood pump is designed with a catheter-mounted impeller, diffuser
blades surrounding the pump hub tip, protective cage filaments and a motor for magnetic
levitation and rotation. The impeller consisted of a hub and 3 counterclockwise oriented
blades and the diffuser was designed with a hub and 4 clockwise oriented blades. Figure 9
outlines the conceptual design of this pump. The development of this pump was completed
through the use of pump design equations and computational fluid dynamics (CFD)
analyses. One of the main objectives of this thesis was to numerically model the interactive
fluid dynamics of the pump and the cavopulmonary circulation in an idealized TCPC
geometry and a patient-specific TCPC geometry.

34

Figure 9: Intravascular Axial Flow Blood Pump for
Cavopulmonary Assist. This intravascular cavopulmonary assist
device consists of a protective sheath, cage filaments, a rotating
shaft and catheter, impeller region and diffuser region. The axial
flow blood pump was numerically modeled in a straight tube to
assess hydraulic performance. Flow entered downstream of the
pump at the inlet(8), traveled through the pump region, accelerated
by the impeller blades(5) and exited at the outlet(9).

3.2 Methods and Materials: Computational Fluid Dynamics
3.2.1 CFD Theory
Computational fluid dynamics (CFD) has been utilized for decades to generate
numerical models for blood flow though arteries, veins, stents, grafts, and blood pumps
[60-63]. Numerical models serve a purpose in the design and development process by
generating reliable predictors of pump performance and flow profiles. The CFD approach
involves the division of a complex three-dimensional fluid domain into a congregation of
smaller, discrete volumetric regions or mesh elements [64]. Mesh elements are linked at
common nodes and through these connections the equations of motion can be algebraically
solved. By characterization and analysis of fluid flow through each discrete node, the fluid
dynamics of the entire fluid domain can be captured. Figure 10 illustrates the
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computational model of the impeller region only, along with the computational element
with nodal locations.

Figure 10: Computational Model of Axial Flow Impeller: A. Meshed model having four regions
– inlet pipe, spindle, impeller with 4 blades, and outlet. B. Numerical analysis involves dividing the
complex three-dimensional fluid model into smaller volumetric regions or mesh elements with
nodes to mathematically characterize the fluid dynamics of the pump.

3.2.2 Software Programs
Several software programs were employed for the CFD work conducted during the
course of this thesis: MIMICS (Materialise, Leuven, Belgium), SolidWorks (SolidWorks
Corporation, Concord, MA), ANSYS (ANSYS Incorporated, Canonsburg, PA), Bladegen
(ANSYS Incorporated, Cansonsburg, PA) and MatLab (The MathWorks Incorporated,
Natick, MA). In order to assess the interactive dynamics between the pump and the TCPC
physiology, two numerical models were created: 1) an idealized TCPC geometry based on
a Ryu et al. [65], and 2) three-dimensional patient-specific models that were constructed
from magnetic resonance imaging (MRI) data of single ventricle patients. MIMICS
software was employed to transform two-dimensional MRI images into a three-
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dimensional point cloud mesh. After numerous smoothing iterations, the three-dimensional
point cloud mesh was imported into SolidWorks to generate a solid body model.
SolidWorks was also utilized for the design and construction of an idealized TCPC model
described by Ryu et al. [65] and elements of the intravascular pump including pump hub
and protective cage. The pump impeller and diffuser blade geometries were generated
using Bladegen. ANSYS-CFX, a 2nd order accurate fluid solver, was employed to simulate
flow through all of the computational models. This CFD program solves the equations for
the conservation of mass and momentum in terms of the dependent variables, velocity and
pressure, according to the Reynolds-Averaged Navier Stokes (RANS) method. The
software Matlab was used to conduct a blood damage study for various pump operating
conditions.

3.2.3 Simulation Models
In order to assess the interactive dynamics between the axial flow blood pump and
physiology numerical simulations were completed in two Fontan models: an idealized
TCPC model generated in SolidWorks and a patient specific TCPC model generated in
MIMICS and SolidWorks.

3.2.3.1 Idealized TCPC
A numerical model of the idealized cavopulmonary connection was constructed
with the intravascular pump integrated in the inferior vena cava (IVC). This work builds
upon the idealized TCPC geometry as described by Ryu et al. [65] and previous studies
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with the intravascular blood pump. The following three models were analyzed: 1) an
idealized TCPC with a 1-diameter offset without a blood pump, 2) an idealized TCPC with
a 1-diameter offset and an axial flow blood pump having only a 3-bladed impeller, and 3)
an idealized TCPC with 1-diameter offset with an axial flow blood pump having a 3bladed impeller and 4-bladed diffuser. Pump placement for models 2 and 3 were in the
IVC. Figure 11 illustrates the three idealized TCPC models.

Figure 11: Idealized TCPC Models. Three idealized TCPC models were generated from
geometry described by Ryu et al. IVC, SVC, LPA, and RPA vessel diameters were set to
13.4 mm. A) Idealized TCPC with no pump. B) Position of the intravascular blood pump
with impeller and diffuser placed in the IVC. Since the position of the intravascular blood
pump with only the impeller is so similar to B), it has not been included. The intravascular
blood pump is placed in the IVC for adult patients with failing single ventricle physiology.
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3.2.3.2 Anatomical TCPC
Provided that actual Fontan patient anatomy retains vascular contours and angles
incapable of being captured in an idealized model, patient specific computational models
were constructed from MRI’s obtained from four Fontan patients. Patient number and
cardiovascular anatomy are provided in Table 3.

Patient Number
1
2
3
4

Anatomy
Extra-Cardiac Fontan
Extra-Cardiac Fontan
Extra-Cardiac Fontan
Glenn

Table 3: MRI Fontan Patient
Information. Four three-dimensional
patient specific Fontan models were
generated from patient MRI images.

Eight three-dimensional models were constructed. Models 1 through 3
demonstrated the extra-cardiac TCPC Fontan anatomy from patients 1-3 respectively.
Models 4 through 6 demonstrated TCPC anatomies from patients 1-3 with an axial flow
pump having a set of impeller and diffuser blades. Model 7 demonstrated a Glenn anatomy
from patient 4, and Model 8 demonstrated a Glenn anatomy from patient 4 with an axial
flow pump having a set of impeller and diffuser blades. Pump placement for models 1-3
were in the IVC and for model 4 was in the SVC. Figure 12 illustrates the four patient
specific TCPC models. Generation of the patient specific three-dimensional solid bodies is
elucidated in Figure 13 for patient 1 corresponding to model 1 and model 5.
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Figure 12: Patient specific anatomical TCPC models. Models 1-4 correspond to patients
1-4 respectively. Models 5-8 correspond to models 1-4 with the axial flow blood pump
place in the IVC for models 5-7 and SVC in model 8.

Figure 13: Generation of a patient specific computational model. A) Point cloud B) 3D suface mesh C) Solid body anatomical model with vascular extensions D) Patient
specific model with pump placement in the IVC.
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3.2.4 Simulation Setup
For this thesis project, the interactive fluid dynamics of the pump and the
cavopulmonary circulation were analyzed numerically an idealized TCPC geometry and
one patient-specific TCPC geometry with the axial blood pump integrated into the IVC.

3.2.4.1 Grid Generation
We employed CFD software from ANSYS Inc. to simulate flow through all
computational models. CFX-Mesh, an ANSYS mesh generation, software was used to build
tetrahedral element-based meshes for the CFD analyses. Grid generation was performed by
other personnel in the research laboratory. Previous grid convergence studies provided
insight as to appropriate regional grid densities for the computational models [25]. Grid
density and convergence studies were completed for grid quality assurance. This process
included incremental adjustments to grid size until the performance results deviated less
than 2%. For each simulation, the incremental time step, or relaxation factor in a steady
state study, was specified as 0.001 to 0.005 with a maximum criterion of normalized
convergence residual at 1x10-3 [61, 66].

3.2.4.2 Configuration and Boundary Conditions
Blood flow through the pump, cage, and total cavopulmonary connections was
defined to be steady with constant boundary conditions and velocities for these
simulations. The no-slip boundary condition was assigned to the stationary walls such that
the fluid velocity values along the boundary would equal zero. A stationary wall boundary
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was applied to the internal housing regions of the pump. The impeller blades and hub were
specified as rotating walls in the counterclockwise direction in accordance with the blade
orientation. The protective cage filaments were modeled as stationary walls, and the
diffuser blades and hub were modeled to be spinning at the same speed as the impeller.
The frozen rotor interface linked regions of differing reference frames between the
impeller domain and protective cage [67]. A uniform mass inflow rate and rotational
speed were specified for each simulation. The outlet boundary surface was specified as an
opening to capture any possible irregular flow conditions at the outflow. The outlet
boundary conditions, such the left and right pulmonary arteries, were defined to have static
pressures of 10, 14, 18, 22 and 26 mmHg. All of the vessel walls for the IVC, SVC, and
pulmonary arteries are modeled as rigid tubes for this initial interactive assessment.

3.2.4.3 Turbulence Model
After successful mesh generation and boundary condition specification, the
computational flow model was then implemented in the 2nd order accurate fluid solver,
ANSYS-CFX. This program solves the equations for the conservation of mass and
momentum in terms of the dependent variables, velocity and pressure, according to the
Reynolds-Averaged Navier Stokes (RANS) method. The RANS method is used to
simulate the entire flow field with acceptable averaged quantities for the mean flow and
fluctuating flow values. Details of the conservation of mass, Navier-Stokes equation of
motion, and Reynold-Averaging procedure are outlined below.
Law of Conservation of Mass
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The differential form of the continuity equation or conservation of mass is derived
by the Eulerian method of analyzing the mass flow into and out of a control volume of
infinitesimal size. As defined using Einstein summation convention the law of
conservation of mass is [68, 69]:
∂ρ
∂
(ρ U i ) = 0
+
∂t ∂xi

[1]

where t represents time, ρ is the fluid density, and Ui is the

three-dimensional velocity vector components of flow summed
over the index i.

Navier-Stokes Equation of Motions
By applying Newton’s law of motion to an infinitesimal fluid element, the
differential form of the law of conservation of momentum is defined in Einstein
summation convention as follows:
∂
∂
∂P ∂τ ij
(
(
[2]
ρ Ui )+
ρ U iU j ) = −
+ ρ fi
−
∂x j
∂xi ∂x j
∂t
where P signifies pressure, τij is the stress tensor, xi
represent spatial variables, and fi is the body force vector.

Neglecting the body force due to gravity, the stress tensor for a Newtonian fluid is:

τ ij = − µ bδ ij

 ∂U
∂U j
∂U k
− µv  i +
 ∂x
∂x k
∂xi
 j






[3]

where µv is the dynamic viscosity, µb = is the bulk viscosity (=2µv,
/3), and δij is the Kronecker delta, a symmetric identity matrix
(when i=j, then δij =1, and δij =0 for i≠j).
Reynolds-Averaging Procedure
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The value of scalar variables fluctuate in turbulent flow conditions therefore the
instantaneous value of a scalar quantity is calculated as the sum of mean and fluctuating
components. Using Reynolds-Averaging, ANSYS-CFX expresses the instantaneous scalar
quantities in terms of mean values, neglecting the fluctuating component [68]. For any
arbitrary quantity θ the instantaneous scalar value is:
__

θ = θ +φ'

[4]

where θ is instantaneous scalar value, θ is the scalar’s mean
component, and φ' represents the scalar’s fluctuating component.

θ , the time-average of scalar’s mean component and φ', the time-average of fluctuating
components are defined as below:
__

1

θ = lim
∆t →∞ ∆t

t + ∆t

∫θ

dt

[5]

t

t + ∆t
____
____
1
[
−
φ ' = lim
θ
θ ] dt = 0
∫
∆t → ∞ ∆t t

[6]

As observed in equation 6 the mean of individual fluctuating components is zero, but the
product of fluctuating components is non-zero. For incompressible flows, the
conservation of mean momentum is derived as below in Reynolds-Averaging form:

___

∂  ____  ∂  ____ _____ 
∂P
∂
−
 ρ Ui  +
 ρ Ui U j  = −
∂t 
∂xi ∂x j
 ∂x j 


_________
 ____

 τ ij + ρ u i ' u j ' 





[7]
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Averaging the left side of the equations using the nonlinear convection term results in the
Reynolds stress tensor ρ u i' u 'j . Eddy viscosity approximations are used to relate Reynolds
stress and turbulent fluctuating terms to mean flow variables resulting in the following
equation:

_____

 ____
Uj  2
∂
 ∂ Ui
ρ u u = −µt 
+
 + ρ δ ij k
∂xi  3
 ∂x j


_______
' '
i j

[8]

where µt is the turbulent viscosity and k is the turbulent kinetic energy term.
The Reynolds-Averaged viscous stress tensor below is defined for incompressible,
Newtonian fluids:
____

τ ij

_____

 ____
 ∂ Ui ∂ U j 
= −µ v 
+

∂xi 
 ∂x j



[9]

The major drawback to Reynolds-averaging is the occurrence of higher order correlations
between the mean and turbulent flow equations thus requiring a ‘closure scheme’ for these
correlations or unknown turbulent stresses. Reynolds stress scheme, turbulent diffusion
model, and two equation models are examples of the numerous closure models utilized for
the RANS approach to model turbulent flow. Turbulence models in CFD codes solve the
nonlinear Reynolds stress tensor in the Navier-Stokes equation by approximating turbulent
flow conditions for the viscous dissipation and kinetic energy transfer. Turbulent viscosity,
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µt, and turbulence kinetic energy, k, are be estimated by electing a turbulence model
suitable for the defined conditions of the numerical simulations.

ANSYS-CFX has a number of different turbulence models, such as the k-ε
turbulence model. The k-ε turbulence model solves the equations for k, the turbulent
kinetic energy, and ε, the dissipation rate of k. The dissipation rate of k or ε is also defined
as the amount of k per mass and time converted to internal fluid energy by viscous motion.
Several research groups have used the k-ε turbulence model for CFD simulations to design
their artificial heart pumps [60, 62, 63]. Along with the k-ε model, we selected a scalable
wall function to characterize and resolve wall flow conditions.

3.2.4.4 Blood Properties
Constant viscosity values were defined for each simulation. The pump model and
patient specific models were held at a constant viscosity value of 0.0035 kg/m*s
corresponding to a hematocrit of approximately 33%, which reasonably represents
pediatric patients suffering from congenital heart disease [70]. Hematocrit influence
studies were conducted on the idealized TCPC model for three blood viscosities: 0.0035
kg/m*s, 0.005 kg/m*s and 0.0065 kg/m*s corresponding to a hematocrit of 33%, 45% and
55% respectively [62, 71]. A constant fluid density of 1050 kg/m3 was also applied to all
simulations.
The behavior of the blood in these simulations was assumed to be Newtonian [69].
At a constant viscosity Newtonian fluids demonstrate a linear relationship between shear
stress and shear strain rate while non-Newtonian fluids exhibit a nonlinear relationship
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between shear stress and shear strain rate. Though the heterogeneous composition of blood
insinuates non-Newtonian behavior, Merrill et al. [72] experimentally found blood plasma
to behave with Newtonian characteristics at a viscosity of approximately 1.2cP. Cokelet et
al. [73, 74] experimentally determined that low hematocrit levels, approximately less than
50%, blood plasma demonstrates a linear relationship between shear stress and shear strain
rate, thus supporting Merrill et al. and confirming the assumption of Newtonian behavior
as acceptable.

3.2.5 Blood Damage Analysis
A blood damage analysis was performed to consider the potential for hemolysis
and thrombosis for this blood-contacting intravascular blood pump. This blood damage
model has been widely employed as a predictive tool in the development of several rotary
blood pumps [71, 75, 76]. We used a blood damage technique that considers the threedimensional flow field and calculates a scalar stress (σ), which includes the six
components of the stress tensor and represents the level of stress experienced by the blood
[77]:


1
σ =  ∑ (σ ii − σ jj )2 + ∑ σ ij2 

6

1/ 2

[10]

We utilized a maximum stress value of 425 Pa for 600 milliseconds as the design criterion
in the development of axial flow VADs [25, 61, 62, 75]. We also examined fluid
streamlines as indicative of numerically predicted fluid residence times within this

47
intravascular blood pump. Using a power law relationship between the scalar stress level
and the exposure time, a blood damage index was estimated for the selected models [76],
according to:

dHb / Hb = C ⋅ σ α ⋅ T β

[11]

where Hb is the hemoglobin content, dHb signifies the change in hemoglobin content due
to blood trauma, σ corresponds to the scalar stress, T is the exposure time to the scalar
stress levels, and C, α, and β reflect proportionality constants that are obtained by
regressing experimental data. The accumulation of stress and exposure time was summed
along the streamlines. This approach provides a statistical estimate of damage to blood
cells traveling through this blood pump, according to the following power law equation:

D=

outlet

∑1.8 x10

−6

⋅ σ 1.991 ⋅ ∆t 0.765

[12]

inlet

where D represents the blood damage index and indicates a ‘probability’ of damage to red
blood cells; t corresponds to the stress exposure time; and inlet and outlet symbolize the
entrance and exit faces in the CFD model, respectively. This model only examined the
relationship between scalar stress and exposure time to the level of stress for each particle;
the analysis incorporated adiabatic and isothermal conditions. To incorporate the stress
history of the particles (cells), a Lagrangian tracking method was used. The particle
displacement was calculated using forward integration of the particle velocity over the time
step (δt):
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dxio
δt
x =x +
dt
n
i

o
i

[13]

where x signifies the displacement and the superscripts o and n correspond to old and new
values, respectively, as the analysis moves forward along the streamlines. The numerical
constants in Equation 3, relating the stress to the exposure time, were obtained by
regression of experimental data in a Couette viscometer with an exposure time of 0.0034 to
0.6 seconds for fluid stresses of 40 to 700 Pa [76, 78]. This range of investigation is
comparable to the flow conditions and stress levels found in blood pumps [76, 78]. We
seek a blood damage index below 2% for our target design [79]. Table 4 lists the details of
this damage analysis, including the case number, number of particles released at the inlet
port and operating conditions.

Table 4: Blood Damage Operational Conditions. Blood damage analyses were
performed on the idealized TCPC model.
Blood Damage Cases
Case 1

Flow Rate (LPM)
3.5

Rotational Speed (RPM)
5000

Fluid Viscosity (cP)
5

Number of Particles

Case 2

3.5

5000

3.5

350

Case 3

3.5

4000

3.5

350

350

Normalized Index of Hemolysis:
Koller and Hawrylenko [80] developed an equation that is routinely used to express
blood damage in the experimental setting as a normalized index of hemolysis (N.I.H):
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N .I .H ( g / 100 L) =

( (

∆fHb × V × 1 − Ht
∆t × Q

100

))×100

[14]

where ∆fHb is the measured increase in plasma free Hb concentration (g/L) during the test
period, ∆t represents the duration of the test period (min), Ht denotes the hematocrit (%), V
corresponds to the blood volume in the test circuit (L), and Q signifies the flow rate
(L/min). This equation is employed in designing heart pumps as well as other bloodcontacting medical devices [81, 82]. The in vitro N.I.H values can be related to the blood
damage index according to the following equation [83].

N .I .H = (0.00015)( D)

[15]

We utilized this empirical relationship to estimate the normalized index of hemolysis in the
computational models that were analyzed in this study and to compare these calculated
N.I.H values to clinically used pumps.

3.2.6 Energy Loss Calculations
To assess the impact of the blood pump in the IVC on the total energy of the
cavopulmonary flow conditions, we used the simplified control volume approach to
calculate the energy losses through TCPC configuration with and without the pump [65].
As a common approach used when considering surgical optimization of the TCPC, this
analysis allowed for the estimation of the energy loss or gain in the cavopulmonary
configuration, according to the following equation:

Eloss = −∑ ( Pstatic + 0.5ρu k u k )u i ni Ai = ∑ (Ptotal _ in )Qinlet − ∑ (Ptotal _ out )Qoutlet

[16]
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where Ptotal = Pstatic + 0.5 ρ u i u i

[17]

Qi = ui Ai [18]
In the aforementioned equations, ρ corresponds to the fluid density, Pstatic is the static fluid
pressure, ui symbolizes the components of the velocity vector, ni is the components of the
outward surface normal vector of the control surfaces, Eloss represents the rate of energy
consumption within the control volume, Ptotal is the total pressure including the static
pressure component in addition to the kinetic energy component, and Qi is the flow rate at
an inlet or outlet. A model of the TCPC alone with no pump in the IVC was created to
directly compare the energy calculations to the model of the TCPC with a blood pump
(impeller and diffuser) in the IVC.

3.2.7 Simulation Execution
Steady state simulations were completed on the idealized TCPC model and patient
specific TCPC model with and without the axial flow blood pump inserted into the IVC.

3.2.7.1 Steady State Simulations
Over 900 numerical simulations were performed as part of this thesis project. Three
main categories of operating conditions were investigated for both the idealized and patient
specific TCPC models: blood flow rate, pulmonary arterial pressure, and pump rotational
speed.
Blood flow rate considerations are critical to the development of any cardiovascular
assist device. The average resting cardiac output (CO) for pediatric and adult patients
ranges from 1 to 8 liters per minute (LPM) [12, 61, 65]. Venous return (VR), or the flow of
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deoxygenated blood from the body back to the heart, emerges to the cardiac musculature
via two great caval veins: the superior vena cava (SVC) and the inferior vena cava (IVC).
The superior vena cava returns deoxygenated blood from the head and upper body and the
inferior vena cava returns deoxygenated blood from the torso and lower body. Under
steady-state conditions VR equals CO where VR is the sum of SVC and IVC flows.
Deriving from anatomical characteristics, VR is dominated by IVC flow for pediatric and
adult patients and almost equally shared by IVC and SVC flows for newborns and infants.
For infants IVC:SVC flow is approximately 50:50 and for pediatric and adults IVC:SVC
flow is approximately 60:40 to 70:30 [12, 65]. The axial flow blood pump simulated for
this thesis work is designed to augment venous return of pediatric and adult Fontan
patients and consequently numerical simulations were conducted for flow rates of 1 to 8
LPM distributed 60% IVC flow and 40% SVC flow.
Pulmonary arterial pressure considerations were also essential to accurate
numerical modeling of the Failing Fontan physiology. On account of the Fontan single
ventricle driving systemic blood flow, VR is transmitted directly to pulmonary circulation.
Considering the cardiovascular system as a closed system, IVC and SVC flow must
overcome pulmonary vascular resistance resulting in an increased after-load on the great
veins whereas in normal biventricular circulation mean caval pressures are less than 10
mmHg and mean arterial pressures are at least 15mmHg [12]. This thesis blood pump is
designed to provide an after-load reducing agent to improve the Failing Fontan
hemodynamics and therefore must be numerical simulated under elevated pulmonary
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resistance conditions. Numerical simulations were conducted for the pressure range 10
mmHg to 26 mmHg in the left pulmonary artery (LPA) and right pulmonary artery (RPA).
The third major operational condition investigated was the axial flow blood pump
rotational speeds. Pump rotation is used to impart kinetic energy on blood flow and is
influential to the pump’s ability to alleviate the poor hemodynamics of the Fontan
physiology. Pump performance to augment venous return is a function of rotational speed
and must be considered over a range of pressures and flow rates. Optimization of pump
design with regard to implementation of diffuser blades and diffuser bladed orientation
were also determined in part by rotational speed influence. Numerical simulations were
conducted for rotational speeds of 1000 to 8000 RPM.
In order to determine the effect of blood viscosity on pump performance, steady
state numerical simulations completed on the idealized TCPC model were performed with
3 blood viscosities: 3.5cP, 5.0 cP, and 6.5 cP corresponding to hematocrits of 33%, 45%,
and 55% respectively [70]. Parameters included all three major operational conditions as
disclosed in the preceding paragraphs.
Fluid particle streamlines and scalar stress values were examined to predict the
potential of hemolysis and thrombosis due to blood contact with the pump. 350 fluid
particles were released at the IVC inlet of the idealized TCPC model for each of 3 blood
damage cases aforementioned in Table 5. Of the 3 damage cases reviewed, 1 was at the
pump design point (Case II) and 2 were off-design point (Case I, III). Off-design point
damage indices were examined since the pump will often be operating off-design. Particle
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residence time on the streamline and scalar stress exposure during contact with the pump
and irregular flow patterns were used for the damage index calculations.
Energy gain calculations for both the idealized TCPC model and the patient
specific TCPC model were completed by conducting simulations on the TCPC models
without the axial flow blood pump. Parameters for the model simulations without pump
included pulmonary arterial pressures of 14 mmHg, fluid viscosity of 3.5 cP, and flow
rates of 1 to 4 LPM in the SVC and IVC.

3.2.7.2 Quasi-Steady State Studies
A quasi-steady state study was performed on the idealized TCPC model with the 3bladed impeller and 4-bladed diffuser axial flow blood pump. The purpose of this study
was to determine the optimal position for the diffuser blades to maximize pressure
generation and to reduce flow vorticity at the outlet. The diffuser blades were
incrementally rotated by 3° and a new grid was created for the diffuser blades at each
rotational position. The new grid at each rotation increment was of the same size (within
1%) and of the same grid quality as compared with the original diffuser model. The new
meshes for the diffuser at each degree increment were then incorporated into the overall
model and a new simulation was completed. Due to the four bladed geometry of the
diffuser region, the achievement of a 90° incremental rotation captures the quasi-steady
performance of the blades. Additional rotations above 90° would be unnecessary given the
symmetry of the diffuser region. The boundary conditions in these simulations remained
the same as for all other simulations conducted during this thesis. 30 different rotational
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geometries and meshes were generated and evaluated for the diffuser region. The
numerical simulations was conducted on the idealized TCPC model with a flow rate of 2
LPM, pulmonary arterial pressures of 14 mmHg, pump rotational speed of 5000 RPM, and
blood viscosity of 3.5 cP correlating to a hematocrit of 33%.

3.2.7.3 Simulations Completed
Numerical simulations completed for pump performance in the idealized TCPC
model and patient specific TCPC model are summarized in Table 5, 6 and 7 below.

Table 5: Summary of steady state numerical simulations.
Fontan Model

Pump Rotational Speed

LPA/RPA Pressure

Flow Rate

Blood Viscosity

Idealized TCPC

1000 -8000 RPM

10 – 26 mmHg

1 – 8 LPM

3.5cP, 5cP, 6.5cP

Patient Specific TCPC

1000 – 5000 RPM

14 – 22 mmHg

1 -5 LPM

3.5cP

Table 6: Summary of quasi-steady state numerical simulations. Simulations were
completed with the idealized TCPC model.
Parameter

Value

Impeller Region

3 Blades

Diffuser Region

4 Blades

Rotational Increments

3o

Flow Rate

2 LPM

LPA/RPA Pressures

14 mmHg

Pump Rotational Speed

5000 RPM

Blood Viscosity

3.5 cP
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Table 7: Summary of blood damage analyses numerical simulations. Simulations were
completed with the idealized TCPC model at steady state.
Blood Damage Cases

Flow Rate

Rotational Speed

Fluid Viscosity

Number of Particles

Case 1

3.5 LPM

5000 RPM

5 cP

350

Case 2

3.5 LPM

5000 RPM

3.5 cP

350

Case 3

3.5 LPM

4000 RPM

3.5 cP

350

3.3 Chapter Summary
This chapter discussed the software employed to design and conduct numerical
analyses on a minimally invasive approach for providing hemodynamic relief and a bridgeto-recovery, -transplant, or -surgical reconstruction to patients with Fontan physiology.
The axial flow blood pump was numerically simulated in an idealized TCPC model and
patient specific TCPC model for performance evaluation under varying physiologic
conditions and pump rotational speeds. Tablatures of all completed simulations were
provided. The subsequent chapter provides results for both modalities investigated for this
thesis work.
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CHAPTER 4 RESULTS

4.1 MAST Clinical Trial Results
Results from this clinical trial with two patients (n=2) agree with literature in that
MAS trousers successfully augmented venous return, systemic pressure, cardiac output,
and blood pressure [55, 57, 84, 85]. Both patients demonstrated significant augmentation
in pressure levels during external pressure application. Common trends with both patients
included an increase in cardiac pressure during inflation holds and return to baseline during
deflation holds. The cyclic inflation/deflation cycles are clearly visible for patient 1;
patient 2 data reflected the cyclic inflation/deflation during the upper range of external
pressure application. This discontinuity between patient cardiac reactions is discussed in
full in the discussion section.
4.1.1 Pressure Augmentation
The three external pressures were applied to the lower limbs of both patients and
abdominal section of patient 1 were determined based upon mean baseline calculations.
Mean baseline diastolic pressure for patient 1 was 47 mmHg; external pressure application
consisted of cyclic inflation/deflation at 37 mmHg, 47 mmHg, and 57 mmHg with
rudimentary rest periods between each level. Patient 2 had a mean baseline diastolic
pressure of 79 mmHg and the external application was cycled at 69 mmHg, 79 mmHg, and
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89 mmHg with similar rests periods between each level. Table 8 below outlines patients’
baseline measurements and applied external pressure levels.
Table 8: Patient baseline and applied external application data.
Patient

Age

Gender

Cardiac Anatomy

1

37

female

Extra-Cardiac Fontan

2

24

male

Intra-Atrial Fontan

Baseline Aortic Pressures (mmHg)
Systolic
Diastolic BP
MAP
BP
94
117

47
79

1st Pressure
Cycle
(mmHg)

2nd Pressure
Cycle
(mmHg)

3rd Pressure
Cycle
(mmHg)

63

37

47

57

92

69

79

89

Patient 1 developed measurable pressure augmentations during all three external
pressure levels; increase in cardiac pressure ranged from approximately 9-15 mmHg in
systolic blood pressure, 4-10 mmHg in diastolic blood pressure, and 5-11 mmHg in
calculated VMAP. Average hemodynamic improvements to patient 1as determined by
pressure increase ranged from 10% during the first cycle at 37 mmHg external pressure to
20% during the third cycle conducted at 57 mmHg external pressure. Figure 12 illustrates
average pressure augmentation measured at the aortic arch as a function of external
pressure application.

Figure 14: Patient 1
aortic augmentation to
baseline pressures as a
function of applied
external pressure.
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Patient 2 also developed detectable pressure rises during cycles of external pressure
application demonstrating systolic pressure augmentation of approximately 10 -13 mmHg,
diastolic increase of 5-7.5 mmHg and improvements to calculated VMAP of 3 – 9 mmHg.
Patient 2 reported lower levels of hemodynamic improvement with dynamic
inconsistencies and unexpected trends discussed further in Chapter 5. Figure 13 illustrates
the average increase in blood pressure as a function of the external pressure application.
Table 9 below outlines the average pressure augmentation for both patients as compared to
the initial baseline measurements.

Figure 15: Patient 2 aortic augmentation to baseline pressures as a function of
applied external pressure.
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Table 9: Average augmentation to systolic, diastolic, and calculated VMAP blood
pressures of patient 1 and patient 2 as compared to baseline measurements. Tabulated
pressures reflect measured quantities obtained at aortic arch of both patients.

Baseline
1
2

External
Pressure
Application
(mmHg)
0
37
47

3

57

97.3

15.3

18.7

57.1

10.1

21.5

70.5

11.5

19.5

Baseline
1
2
3

0
69
79
89

117
127.2
130.1
127

-10.2
13.1
10

-8.7
11.2
8.5

79
84.5
86.5
85.6

-5.5
7.5
6.6

-7.0
9.5
8.4

92
98.7
101
98.9

-6.7
9
6.9

-7.3
9.8
7.5

Patient 2

Patient 1

Cycle
Number

Systolic
BP
(mmHg)

Systolic
Augmentation
(mmHg)

Systolic
Augmentation
(%)

Diastolic
BP
(mmHg)

Diastolic
Augmentation
(mmHg)

Diastolic
Augmentation
(%)

MAP
(mmHg)

MAP
Augmentation
(mmHg)

MAP
Augmentation
(%)

82
91.6
94.9

-9.6
12.9

-11.7
15.7

47
51.1
54.2

-4.1
7.2

-8.7
15.3

59
64.6
67.8

-5.6
8.8

-9.5
14.9

All systolic and diastolic pressures are functions of aortic pressure obtained from a
catheter mounted pressure transducer placed in the aortic arch of both patients. Increases in
aortic pressures were noticeable in patient pressure waveforms generated from the pressure
transducer floating in the aorta. Figure 16 illustrates the increase in aortic pressures due to
external pressure application for patient 1 and patient 2 during a selected inflation cycles.
Figure 17 illustrates the calculated aortic MAP augmentation during 1 inflation/deflation
cycle for patient 2.
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Figure 16: Sample pressure data from external pressure augmentation obtained
during cardiac catheterization. A) Patient 1 during upstroke of external pressure
application at 47 mmHg. B) Patient 2 during upstroke of external pressure application at 69
mmHg.
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Figure 17: Aortic MAP augmentation during 1 cycle for patient 2.

4.2 Numerical Simulation Results
Figure 18 illustrates the percutaneous, magnetically levitated and rotated axial flow
blood pump designed as the minimally invasive approach for augmentation of Failing
Fontan hemodynamics. Over 900 numerical simulations were completed to optimize pump
design and test pump performance, quantifying its effectiveness at augmenting flow and
providing hemodynamic relief to Fontan patients. Simulations were conducted in 2 extracardiac three dimensional models, an idealized TCPC and a patient specific TCPC
generated from MRI data, investigating multifarious physiologic conditions including
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combined IVC and SVC flow rates of 1 to 7.5 LPM, pulmonary arterial pressures (LPA
and RPA) of 10 to 26 mmHg, and blood viscosities of 3.5cP, 5.0 cP, and 6.5cP. The follow
sections detail the results from these simulations.

Figure 18: Intravascular, magnetically levitated and rotated, axial flow blood pump.
Pump is designed to provide a minimally invasive method to alleviate poor hemodynamic
associated with Failing Fontan physiology.

4.2.1 Pump Pressure Curves
The pressure generation across the intravascular blood pump in the idealized TCPC
model was determined for flow rates of 1 to 7.5 LPM and pump rotational speeds of 3000
to 8000 RPM. Figure 19 illustrates the hydraulic performance of the idealized TCPC
model. Each data point is indicative of a steady state simulation at a specific flow rate and
rotational speed. The pump delivered a range of pressure rises from 2 to 26 mmHg for
these operating conditions. Additionally, pressure rise across the pump increased with an
increase in rotational speed and decreased with an increase in flow rate, as to be expected.
The pressure curves demonstrate the axial flow pump’s capabilities to provide acceptable
pressure generation for the physiologic conditions.
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Figure 19. CFD predictions of the hydraulic performance of the blood
pump in the Idealized TCPC model. Pressure generation across the axial
flow blood pump with impeller and diffuser blades. Simulations were
completed with flow rates of 1 to 7.5 LPM, rotational speeds of 3000 to
8000 RPM, and pulmonary arterial pressure set at 14 mmHg.

Figure 20 compares the axial flow blood pump design with and without a set of
diffuser blades located at the pump head. The model with diffuser blades operated at
reduced rotational speeds and generated more than twice as much pressure head across the
pump. The pump with diffuser blades outperformed the pump without diffuser blades over
both investigated units (flow rate and rotational speed) thus demonstrating an improvement
to previous pump design work.
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Pressure Rise (mmHg)
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2

2.5

3

3.5

4

4.5

5

5.5

6

6.5

7

Flow rate (LPM)
4000 RPM - w/ Diff
10,000 RPM - w/o Diff

5000 RPM - w/ Diff
11,000 RPM - w/o Diff

6000 RPM - w/ Diff
12,000 RPM - w/o Diff

Figure 20: CFD predictions of the hydraulic performance of the blood pump in
the Idealized TCPC model. Two blood pump designs were considered. One model
had the protective cage, catheter, and an impeller blade set only. The other model
included a set of diffuser blades at the outflow of the pump. Flow rates of 1 to 6.5
LPM were simulated for a wide range of rotational speeds of 4000 to 12,000 RPM.

The diffuser blades increased pressure rise across the pump by reducing the fluid
velocity thus transferring energy to pressure as in accordance with conversation laws.
Figure 21 below illustrates the reduction in fluid velocity of blood flow exiting the
impeller region and associated total pressure contour across the pump. Fluid velocity
augmented by rotating impeller blades was reduced by the counter orientated rotating
diffuser blades, transferring the velocity augmentation to pressure augmentation.
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Figure 21: Diffuser blades reduce fluid velocity and increase pressure.
Figure 22 illustrates pressure rise across the pump and pressure decrease at the IVC
inlet as a function of pump rotational speed for the idealized TCPC. Conditions for the
comparison included flow rates of 1 to 4 LPM for rotational speeds of 2000 to 6000 RPM
and pulmonary pressures of 10 to 26 mmHg. The IVC pressure is decreased as the pump is
rotated faster, as would be expected. Additionally, higher arterial pressures lead to higher
IVC pressures.

Figure 22: Pressure rise across the axial blood pump in the idealized TCPC model and the
IVC pressure as a function of increasing rotational speed. (A) This graph illustrates the trends
of the pressure rise across the pump to increase with increasing rotational speeds, as would be
expected. In addition, the pressure rise is lower for a higher flow rate at a given rotational speed,
as would theoretically be expected. (B) This graph shows the impact of the blood pump on the
IVC pressure on the inlet side of the pump as a function of increasing rotational speed and
pulmonary arterial pressures at a blood flow rate of 5 LPM.
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The pressure generation across the intravascular blood pump in the anatomical
patient specific TCPC model was determined for flow rates of 1 to 5 LPM and pump
rotational speeds of 2000 to 5000 RPM. Figure 23 illustrates the hydraulic performance of
the anatomical TCPC model. The pump delivered a range of pressure rises from 1 to 7
mmHg for these operating conditions. As observed in the idealized TCPC model, pressure
rise across the pump increased with an increase in rotational speed and decreased with an
increase in flow rate.

Figure 23: CFD predictions of
the hydraulic performance of
the blood pump in the Patient
Specific TCPC model. Pressure
generation across the axial flow
blood pump with impeller and
diffuser regions. Data represents
simulations conducted at
LPA=RPA=14 mmHg for flow
rates of 1 to 5 LPM and pump
rotational speeds of 2000 to 5000
RPM.

Figure 24 demonstrates the influence of pump rotational speed on IVC inlet
pressure for the anatomical TCPC model. As expected, pressure at the IVC inlet decreased
as a function of increased pump rotational speeds. Parameters for these results included
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flow rates of 1 to 5 LPM, pump rotational speeds of 2000 to 5000 RPM and
LPA=RPA=14mmHg.

Figure 24: Pressure rise across the axial blood pump in the patient specific TCPC model and the
IVC pressure as a function of increasing rotational speed. (A) Pressure rise across the pump to
increases with increasing rotational speeds, as would be expected. Pulmonary arterial pressures were set
to 14mmHg for these comparisons. (B) This graph shows the impact of the blood pump on the IVC
pressure on the inlet side of the pump as a function of increasing rotational speed and pulmonary arterial
pressures at a blood flow rate of 5 LPM.
4.2.2 Flow Profile
Careful analysis of flow fields are critical to the development of a axial flow pump
designed for augmentation of the cardiovascular system. Irregular flow patterns such as
vortices, eddies, and flow stagnation could increase blood exposure to high levels of shear
stress activating thrombolytic factors or erythrocyte hemolysis. Figure 25 below illustrates
the flow profiles for the axial flow blood pump with and without diffuser blades. The
streamlines for both pump models were generated at a fluid flow rate of 3.5 LPM and
pump rotational speeds of 5000 RPM. The inclusion of the diffuser blades accomplished a
reduction in swirling and vortices at the pump outlet, but did not complete eliminate the
irregular flow. Additionally the streamlines of the pump model with a diffuser exhibit
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lower particle velocities at the outlet as compared to the pump model without a diffuser,
indicating a reduction in fluid velocity and thus an increase in pressure as confirmed in the
previous section.

Figure 25: Reduction in Vorticity due to diffuser blades. The diffuser blades are able to
redirect flow at the outlet and reduce the outflow vorticity, however not able to eliminate
the flow swirl as intended.

Fluid streamlines through the idealized TCPC are displayed in Figure 26 and
anatomical patient specific TCPC model 1 with and without the intravascular blood pump
are displayed in Figure 27. The fluid streamlines correspond to operating conditions of
pulmonary pressures of 14 mmHg, blood flow rate of 3.5 LPM, and pump rotational speed
of 5000 RPM. Strong rotational flows were found at the outlet of both pump models,
dissipating some through the pulmonary arteries.
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Figure 26: Fluid streamlines for the idealized TCPC model with and without the
intravascular pump. Idealized model streamlines without pump (A) display high velocity
turns at the outer boundaries of caval veins and pulmonary arteries connection points. (B)
Velocity increases at IVC outlet due to axial flow pump.

Figure 27: (A) Fluid streamlines for patient specific TCPC model without the
intravascular blood pump. Lowest fluid velocities are observed at the inner boundaries of
the TCPC. (B) Increased fluid particle velocities observed due to axial flow blood pump.
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4.2.3 Scalar Stress Distributions
Scalar Stress represents a calculated weighted average of the shear and normal
stresses and is useful for determining the level of blood trauma during pump operation.
Figure 28 displays the scalar stress distribution through the intravascular cavopulmonary
pump model along the rotor hub. At the design point, the highest fluid stresses of 125 Pa
were estimated to exist along a small regional surface area at the leading edge of the
impeller blades and more substantially along the impeller blade tips.

Figure 28: Scalar stress estimations on
the impeller and diffuser hub surfaces.
The magnitude of the scalar stress
remained below 125 Pa with the highest
stress regions along the impeller blade tip
surface. Higher stresses were predicted at
the blade tip when in closer proximity to
the protective cage filaments.

Similarly, Figure 29 illustrates the scalar stress levels along the surfaces of the
protective cage of filaments. The magnitude of the scalar stress remained below 120 Pa
with the highest stress regions in closer proximity to impeller blade tips. These regions of
high scalar stress are attributed to the interaction between the impeller blade and cage
filaments.
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Figure 29: Scalar stress estimations on
the cage filament surfaces. The
magnitude of the scalar stress remained
below 120 Pa with the highest stress
regions of closer proximity to impeller
blade tips.

4.2.4 Blood Viscosity Effects
In consideration of the target patient population and their varying blood viscosity
values, Figure 30 illustrates the results of the viscosity study performed on the Idealized TCPC
model and the impact on pump performance. It was determined that IVC pressure varied little
for higher viscosity values at lower rotational speeds. This sensitivity appeared to increase to
approximately 8.5% at 5000 RPM. The pressure rise across the pump was also not sensitive to
increasing viscosity values at all rotational speeds with a deviation averaging 4.6%.
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Figure 30: Effect of Blood
Viscosity on Pressure in the
IVC and Pressure Rise across
the Pump as a function of
pump rotational speed. (A)
Adjustments to IVC pressure due
to the pump rotational speeds
varied little for higher fluid
viscosity values, indicating the
versatility of the pump to
accommodate a range of possible
patient conditions. (B) Pressure
rise across the pump was
maintained over all rotational
speeds without reduction or
measurable change due to
increasing viscosity.

4.2.5 Quasi-Steady State Study
In order to detect the optimal axial rotational orientation of the impeller and
diffuser blades a quasi-steady state study was performed for the cavopulmonary blood
pump. Figure 31 illustrates the computational predictions from the quasi-steady analysis of
the diffuser blades and their impact on pressure generation as a function of rotation
position. Thirty simulations were completed for rotational increments of 3 degree. This
study was performed at 5000 RPM and 2 LPM. According to the numerical findings, the
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diffuser blades having a rotational position of 12 degree produced the largest pressure
generation across the pump. The predicted improvement in pressure rise was found to be
6%. The diffuser blades having a rotational position of 57 degree generated the lowest
pressure across the blood pump. A pressure reduction at the 57 degree position was found
as compared to all other rotational positions. In comparison of the pressure generation at
the initial design position at 0 degree (10 mmHg), the 57 degree rotation of the diffuser
blades resulted in a pressure generation decrease of 37% (6.3 mmHg).
12o

57o

Figure 31: Quasi-steady study of the
rotational impact for the diffuser
blades. This study was performed at
5000 RPM and 2 LPM. The diffuser
blades having a rotational position of
12 degree produced the largest
pressure generation across the pump.
The diffuser blades having a rotational
position of 57 degree generated the
lowest pressure across the blood pump.

4.2.6 Blood Damage Analysis
In addition to the quasi-steady study, a blood damage analysis was conducted to
consider the potential for hemolysis from blood contacting the pump. This approach
releases massless, inert particles at the inlet and tracks using streamlines their exposure
time to fluid stresses. It uses a power law relationship between the scalar stress values and
the exposure time to estimate an accumulated blood damage index for each particle. The
blood damage analysis was completed on the idealized TCPC model to approximate the
level hemolytic and thrombotic factors incurred due to blood contact with the intravascular
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blood pump. Figure 32 displays the results of the numerical blood damage analysis. Three
cases with a pump flow rate of 3.5 L/min were considered in this analysis: 1) a fluid viscosity
of 5 cP and rotational speed of 5000 RPM, 2) a fluid viscosity of 3.5 cP and rotational speed of
5000 RPM, and 3) a fluid viscosity of 3.5 cP and rotational speed of 4000 RPM. Table 10 lists
these cases and their corresponding results, as discussed in the subsequent sections.

Figure 32: Blood damage indices and particle residence times for the idealized TCPC
model. Intravascular blood pump operating conditions, fluid viscosities, and LPA/RPA
arterial pressures as specified in Table 4. (A) Case I, (B) Case II and (C) Case III results.
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Table 10: Blood damage analysis details and finding for the Intravascular
Axial flow blood pump and the Idealized TCPC model.
Blood Damage
Case Number

Case 1

Flow
Rate
(LPM)
3.5

Rotational
Speed
(RPM)
5000

Fluid
Viscosity
(cP)
5

Number
of
Particles
350

Mean
Damage
Index
0.110%

Maximum
Damage
Index
0.990%

Mean
Residence
Time(sec)
0.2724

Maximum
Residence
Time(sec)

Case 2

3.5

5000

3.5

350

0.130%

0. 800%

0.3754

0.3990

Case 3

3.5

4000

3.5

350

0.0549%

0.280%

0.4222

0.5160

0.3740

4.2.7 Energy Gain
In addition to the blood damage analyses, energy losses due to the cavopulmonary
connection are of general concern due to associated pathophysiologies deriving from the
loss of the pulmonary ventricle. A simplified control volume approach was used to
calculate the hydraulic energy of the both TCPC models with and without the axial flow
blood pump placed in the IVC. Figure 33 demonstrates the energy gain due to mechanical
assistance of the idealized TCPC with the pump design having an impeller and diffuser
blade set. These simulations occurred at an operating condition with left and right
pulmonary arterial pressures of 14 mmHg, a fluid viscosity of 3.5 cP, a range of flow rates
from 1 to 3.5 L/min, and two rotational speeds of 4000 and 5000 RPM. In comparison to
the energy loss associated with the idealized TCPC without mechanical support, the
predictions indicated that the use of the pump to mechanically augment pressure in the
IVC increases the hydraulic energy of the TCPC as a function of both increasing rotational
speed and flow rate.
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Figure 33: Energy Gain due to mechanical assistance of the idealized TCPC with a
blood pump in the IVC. Mechanical assistance of the IVC pressure enhanced the
hydraulic energy within the TCPC as compared to conditions without pump support.
Figure 34 demonstrates the energy gained due to mechanical assistance with the
pump as compared to the energy lost due anatomy and physiology in the patient specific
TCPC model. These calculations were made for the following operating conditions: left
and right pulmonary arteries at 14mmHg, flow rates from 1 to 4 LPM, and pump rotation
speed of 5000 RPM. As observed in the idealized energy calculations, the introduction of a
circulatory assist device to the Fontan anatomy significantly increases the hydraulic energy
of blood flow thus mitigating the loss from a lack of pulmonary ventricle.
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Figure 34. Energy Gain due to mechanical assistance of the patient specific TCPC with a
blood pump in the IVC. Mechanical assistance of the IVC pressure enhanced the hydraulic
energy within the patient specific TCPC as compared to conditions without pump support.

4.3 Chapter Summary
Based upon the results of numerical simulations of the two pump models and two
extra-cardiac Fontan models, the intravascular axial flow blood pump was optimized in
design as follows: an impeller with 3 counterclockwise helically wrapped blades, a diffuser
region with 4 clockwise helically wrapped blades at a 12o offset to the impeller, and
protective cage with 5 filaments. The optimized pump generates pressure rises of 2 to 25
mmHg for flow rates of 1 to 7.5 LPM and rotational speeds of 2000 to 8000 RPM, reduces
irregular flow perturbations at the pump outlet, and demonstrates low probabilities for
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erythrocyte damage. Table 11 outlines the design specifications and numerical results of
the optimized intravascular, axial flow blood pump.
Table 11: Summary of Axial Flow Blood Pump Design Specifications and Results
Design Specifications and Investigations
Impeller Blade Count
Impeller Blade Orientation
Diffuser Blade Count
Diffuser Blade Orientation

Numerical Results
3
Counter-clockwise
4
Clockwise

Impeller-Diffuser Optimal Rotational Offset

12o

Axial Flow Blood Pump Pressure Generation

1 - 26 mmHg

Blood Flow Rates
Pulmonary Arterial Pressure

1 - 7.5 LPM
10 -26 mmHg

Pump Rotational Speed

1000 - 8000 RPM

Maximum Scalar Stress

125 Pa

Maximum Blood Damage Index

0.99%

Mean Blood Damage Index

0.10%

Maximum Residence Time

0.516 sec

Mean Residence Time

0.35667 sec

Maximum Energy Gain (Idealized)

45 mW

Maximum Energy Gain (Patient Specific)

27 mW
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CHAPTER 5 DISCUSSION
Fontan and Baudet introduced the total right heart bypass in 1968 [86, 87]. Decades
prior to their original description, at least 40 different experimental procedures to bypass
the right heart provided evidence that venous pressure alone could act as the driving force
for blood flow into pulmonary circulation. The current treatment paradigm for patients
with univentricular physiology is a staged surgical palliation, leading to a Fontan
conversion. Several modifications to the Fontan have developed over time with the TCPC
providing a direct connection from the superior and inferior vena cava to the pulmonary
arteries. In the absence of a pulmonary ventricle, the blood traveling through the Fontan
circulation experiences a loss of energy with minimal to no pulsatility as it flows through
the pulmonary circulation [1-4, 10, 11, 15, 65, 88]. Secondary pathologies due to the new
“man-made” physiology include reduced preload, diminished exercise capacity,
supraventricular arrhythmias, protein losing enteropathy, aortopulmonary and veno-veno
collateral vessels. It has been theorized that the long-term effects of the Fontan paradox
(caval hypertension and relative pulmonary hypotension) can be reversed through
mechanical support [22, 49, 61].
This thesis documented the methods, materials, and results for two mechanical
cardiovascular assist devices designed to augment the hemodynamics of adolescent and
adult Fontan patients. A non-invasive method for circulatory support provided via
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counterpulsation external pressure technology was described in Chapter 2 and the results
were outlined is Chapter 4. Likewise, the minimally invasive method using an
intravascular axial flow blood pump inserted into the IVC was described in Chapter 3 with
numerical simulation results outlined in Chapter 4. Discussions for each method of
mechanical cardiovascular assist are in the sections below.

5.1 Non-invasive External Pressure Augmentation
The goal of the non-invasive cardiovascular assist modality was to develop and
design an innovative non-invasive medical device for the prevention and/or treatment of
pathological implications in postoperative Fontan patients adjusting to their new “manmade” physiology. This device would provide cardiovascular assistance to patients through
the augmentation of systemic blood flow to the pulmonary arteries, thus increasing venous
return and pulmonary perfusion, and reducing cardiac afterload. The device operates
through the medium of external pressure application to the lower limbs and abdomen,
forcing forward propulsion of blood towards the heart and pulmonary circulation,
analogous to muscular contractions during exercise. For this thesis clinical trials were
completed utilizing retrofitted MAS trousers as the channel for external pressure
augmentation. Positive results from the clinical trials serve as the clinical feasibility study
for development of a novel external cardiovascular assist device for patient use at home.
Subject recruitment began immediately after we received Virginia Commonwealth
University IRB approval in January 11, 2009 (VCU IRB #HM11906).
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Two patient trials were completed during the first year of the IRB approved clinical
investigation. Clinical trial subject population was limited due to exclusion criteria and
reduced qualified candidate pool of a unique cohort of cardiovascular defects. The first
clinical trial occurred February 19, 2009 with Dr. William Moskowitz conducting the
cardiac catheterization on a 37 year old female single ventricle patient with a TCPC extracardiac Fontan anatomy. Results indicated an increase in pressure of approximately 4 -15
mmHg for systolic and diastolic pressure measured in the aortic arch. As illustrated in
Figure 14, trends in patient 1 data demonstrate almost a linear correlation with increases in
external pressure application providing evidence that the application of external pressure
increased venous pressures which translated to an increased of blood flow to pulmonary
circulation and subsequently the aortic arch.
In contrast to patient 1, patient 2 did not demonstrate the expected linear correlation
between the external pressure application and resulting influence in aortic blood pressure.
Several considerations and speculations can be offered as explanation for the unexpected
trends exhibited by patient 2. The second clinical trial occurred on October 6, 2009 with
Dr. William Moskowitz conducting the cardiac catheterization on a 24 year old male single
ventricle patient with a classical Fontan with the right atrium is preserved, also known as
an intra-atrial Fontan. During the clinical trial, the abdominal section was neglected due to
the patient’s medical history of sleep apnea posing as exclusion criteria for any external
pressure application with possible respiratory constriction affects. Hepatic vessel
compliance during pressure application to the lower limbs may account for a portion of the
pressure dissipation downstream of the heart. The patient’s Fontan anatomy may have also
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contributed to the reduced response of external pressure application due to compliance of
the intact right atrium expanding to accommodate the increased volumetric blood flow.
Additionally during the catheterization, observations were made with patient respirations
and correlations to patient pulmonary arterial pressures. During deep sleep it was noted
that the patient’s inspiration and expiration had discernable affects on pulmonary arterial
pressures, thus insinuating observed pressure augmentation to aortic blood pressure may
not be independent of respiratory cycle.

5.2 Minimally Invasive Intravascular Blood Pump
In support of the development of a minimally invasive cavopulmonary assist
device, this thesis outlined the results of numerical analyses on an intravascular blood
pump placed in Fontan TCPC models. The mechanical circulatory device is a collapsible,
percutaneously inserted, axial flow blood pump designed to function as a bridge-totransplant or bridge-to-recovery for adult Fontan patients. Description and placement of
the pump can be found in Figures 9 with a full detail presented in previous chapters.
Extensive numerical studies were conducted to test pump performance in an
idealized TCPC model and a patient specific TCPC model. Left and right pulmonary
arterial pressures were examined at five pressure points from 10 mmHg to 26 mmHg, blood
viscosities from 3.5cP to 6.5 cP, and pump rotational speeds from 1000 RPM to 8000
RPM. The pump demonstrated hydraulic performance as quantified by pressure
generations of 1 to 25 mmHg over flow rates of 1 to 7.5 LPM. This range of pressure rises
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and flow rates is sufficient to support an adolescent and adult Fontan patient. Hydraulic
performance curves were characteristically consistent for varying rotational speeds.
Fluid viscosity influences were found to be minimal with greater effects found at
higher rotational speeds as demonstrated in Figure 30 in chapter 4. The low influence of
higher fluid viscosities on pump performance is important since a majority of Fontan
patients are polycythemic, thus having a wide range of blood hematocrits. A versatile
pump design that is not subject to performance losses over a range of blood hematocrits is
advantageous for Fontan patients.
Blood damage analyses were performed on three cases, all of which resulted in a
maximum damage index of less than 1% and maximum residence time of less than 0.52
seconds indicating a low probability of blood damage due to interaction with the pump.
Two cases were performed off design point of the pump reflecting the position that the
pump will often function off ideal design parameters. The majority of tracked particles
indicated an even lower probability of damage as demonstrated in Figure 32 and Table 10
in Chapter 4. The maximum blood damage indices also predict a very low N.I.H for these
operating conditions examined. Blood pumps are designed to maintain an N.I.H level
below 0.005 g/100L for clinical use. The predicted N.I.H values remained one to two
orders of magnitude lower than the cutoff limit for clinical use. Table 12 below outlines
the results from the blood damage analyses as compared to selected clinically available
adult rotary blood pumps. Estimations indicate that centrifugal blood pumps have damage
indices of 4% to 6% [79] and axial blood pumps have higher indices, ranging from 19% to
40% [61]. Based on this comparison and the number of particles used in this study, these
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results suggest that a majority of the tracked particles have a low probability of damage,
however blood bag experimentation must be performed to quantify the levels of hemolysis
for this intravascular blood pump.

Table 12: The comparison of blood damage indices and N.I.H values for selected
adult rotary blood pumps.[51, 61, 89-92]
Pump
Valvo Pump
MicroMed-DeBakey
Biomedicus BP-80
Berlin Incor I
HeartMate II
Intravascular Pump*

Type

N.I.H. (g/100L)

Damage Index (%)

Axial
Axial
Centrifugal
Axial
Axial
Axial

0.030
0.0028
0.0007
0.006
0.005
---

200
19
5
40
33
1

To analyze the interactive dynamics between the pump and the TCPC, we
calculated the energy of the total system using a simplified control volume approach. This
technique has been commonly used by researchers and clinicians to maximize surgical
optimization of the TCPC and elucidate new surgical strategies to mitigate hydraulic
energy losses [65]. Under conditions where no artificial right ventricle or subpulmonary
power source exists, such as those present in the Fontan physiology, energy losses
invariably occur with blood flow in the TCPC and subsequent flow into the LPA and RPA.
Previous studies found the energy losses (i.e. power loss) in the TCPC to increase due to
higher flow rates, lower limb exercise, dramatic changes in the geometry of the
anatosmoses, and lack of caval offset [93]. By incorporating a blood pump into the IVC,
energy augmentation is observed, rather than hydraulic losses. This positive augmentation
of energy due to the pump in the IVC is the intended result and may translate into an
improvement in venous return and cardiac output for Fontan patients. In conjunction with
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surgical optimization of the TCPC, the introduction of periodic or short-term
cavopulmonary assist may serve as a viable, long-term, clinical management strategy for
Fontan patients.
Figure 33 in Chapter 4 illustrates the energy losses of the idealized TCPC without a
pump in the IVC in comparison to the energy gains of the idealized TCPC with the
intravascular pump (impeller and diffuser blade set) in the IVC. Pump rotational speeds of
4000 RPM and 5000 RPM were examined to determine the energy augmentation in the
idealized TCPC. A steady increase in energy as a function of flow is observed from 1 to
3.5 L/min for the 4000 RPM operating conditions. Upon reaching 4 L/min, the energy
performance curve at 4000 RPM ceases to increase in slope; the inherent hydraulic losses
from this higher flow rate through the idealized TCPC and the lower head produced by the
pump begin to inhibit energy augmentation. For the 5000 RPM operating condition, the
pump is able to continuously improve energy gains over the entire 1 to 4 L/min flow range.
Similar trends were observed for the patient specific TCPC Fontan model. The energy gain
from the pump in the patient specific TCPC model peaked under 30mV with similar linear
trends indicating that increase in flow rates at give pump RPM would result in increased
energy gain.
In examining the outflow conditions of the pump, a rotational component of the
flow was predicted by the computational analysis. The introduction of a diffuser region
consisting of a hub with 4 clockwise helically wrapped blades demonstrated a reduction in
vorticity at the outlet of the pump as compared to previous models without a diffuser
region. Figure 25 illustrates the diminution of rotational fluid flow at the outlet region of
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the pump. Complete elimination of irregular flow patterns were not achieved thereby
requiring the above discussed analyses of energy gain and blood damage indices. Despite
the rotational flow component, power or energy enhancement was achieved, and low blood
damage indices were predicted. Additional design work will be performed to minimize this
flow rotational and straighten the blood flow leaving the pump.
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CHAPTER 6 FUTURE WORK AND CONCLUSIONS
6.1 Limitations and Future Work
Previous chapters discussed two novel approaches for the development of
mechanical circulatory devices for Fontan patients. A non-invasive method using external
pressure augmentation to the lower limbs demonstrated notable increases in systolic and
diastolic blood pressures for in two patients. A minimally invasive method using a
percutaneously inserted, intravascular blood pump computationally demonstrated
acceptable pressure generations to augment the Failing Fontan hemodynamic. Both
modalities show promise in the clinical support and treatment of Fontan patients: the
pressure pants as long-term preventative support and axial flow blood pump for short term
bridge support. Study limitations are discussed in this chapter along with issues to be
addressed in future work.
6.1.1 Pressure Garment
A considerable limitation to thesis work with regard to the pressure garment
clinical trials was the lack of test subject population. During the year and a half time frame
of the VCU IRB approved clinical trials, only two patients successfully met the criteria and
participated in the study. Factors influencing the deficiency in subject population include
the diminutive single ventricle Fontan cohort perpetuated by a single intuitional
investigation and extensive exclusion criteria inclusive of several secondary pathological
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conditions common to Fontan patients. Future clinical studies for continued development
of the pressure garment will address these limitations by seeking multi-institutional clinical
trials.
During development of the clinical external pressure augmentation protocol several
inflation/deflation intervals and timings were considered. Interval cycles excogitated for
the clinical trial included cardiac cycle synchronization, respiratory cycle synchronization
and constant interval based. Research indicates that the majority of clinical external
pressure pulsation devices are synchronized to the patient’s cardiac cycle thus requiring
more advanced technology and a nurse or technician to monitor and operate the device for
proper synchronization. Having stated our predispositions of EECP delivery with
accordance to synchronization protocol in Chapter 2, it was inferred that counterpulsasive
therapy less synchronization will also demonstrate beneficial results. This assumption was
strongly supported by the results this study in addition to the reviewed literature.
Discrepancies arise, however, when attempting to decipher the degree of assistance
provided by counterpulsation administered at a basal rate unlinked to a patient’s cardiac
cycle. If future work includes investigation of cardiac synchronization, it is expected that
cardiac synchronization is significant to the level of augmentation provided by
counterpulsation, however the occurrence of such augmentation is independent of
synchronization.
Respiratory cycle synchronization was also considered. Chest wall expansion during
inhalation and subsequent depression during exhalation influence cardiac filling and
ejection. Upon deep inhalation, the second heart sound can split providing audible
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evidence of a delay between the closing of the pulmonary and aortic valves. Though
respiratory synchronization effects would have been interesting to investigate, it was not
included due to the overall goal of developing a therapeutic device for patients to use at
home, thus requiring a simpler model. However, due to correlating respiration cycle and
pulmonary arterial pressures observations made during the second patient’s clinical trial,
continued development of an external mechanical cardiac assist device would include
respiratory cycle synchronization analyses.
Based upon the need for a simple device designed to augment venous flow a
constant interval cycle was determined to be the favorable timing for pressure garment
inflation and deflation. The constant interval cycle was conducted as a square wave, with
inflation demonstrated as the highpoint when the pressure is applied and deflation as the
lowpoint when the pressure is removed. An ideal square wave interval cycle would
demonstrate precision in holding the pressure at a specific target and instantaneous
inflation and deflation. Though based on the ideal, the clinical trial conducted with
retrofitted medical anti-shock trousers resembled more of a trapezoidal wave with sloping
increases and decreases in pressure during cycles. Additionally, during the inflation hold
periods loss of pressure may be exhibited do to leaks within the pressure pant system. With
these limitations considered, it was determined that for the purpose of augmenting venous
blood flow to the heart, slight fluctuations in external pressure are inconsequential and thus
do not contravene the use of a constant interval cycle nor discount the integrity of trial
results. However future work with the pressure garment will not only reconsider the before
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mentioned synchronization affects but also reduce pressure loses during inflation holds by
identifying and subsequently rectifying system leaks.
The VCU/MCV catheterization laboratory employs SIEMENS (Siemens
Corporation, New York, NY) technology. The current software package conducts real-time
analyses and stores user defined values or pressure waveform moments at a defined time.
Continual recording of pressures for analysis at a later time is outside the software
capabilities thus limiting the view of external pressure augmentation influence on patient
hemodynamics. Additionally, the software is confined to output averaged pressures for
selected waves and incapable of outputting discrete data, greatly influencing the accuracy
of data analyses.

6.1.2 Intravascular Blood Pump
This thesis work on the intravascular blood pump has a number of limitations that
must be addressed during the next stage of development. The boundary conditions as
specified are for steady flow analyses; transient flow simulations and fluid structure
interaction (FSI) studies with varying inlet and outlet impedances, vessel compliance, and
lung compliance would provide more accurate information about the interactive dynamics
between the physiology and the blood pump. A detailed turbulence model study would
also generate valuable insight into the fluid dynamics.
The manufacturing of three-dimensional models of the idealized Fontan TCPC
anatomy and patient specific TCPC anatomy with inclusion of the pump prototype in the
IVC is currently underway. These models will allow for laser flow measurements and
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hydraulic performance testing to take place and to validate numerical predictions from this
thesis.
The blood damage analyses conducted with the idealized TCPC model did not
consider heat transfer, platelet activation, and transient effects in the fluid stresses due to
blade rotation. Additionally, the blood damage analysis uses a power law equation
generating overestimations in the levels of hemolysis. The overestimation, however, allows
pump design to err on the side of caution. Hemolysis testing using physical prototypes
would provide more realistic confirmation of actual trauma levels.

6.2 Conclusions from Research
This thesis presented two novel approaches for the development of a mechanical
cardiovascular assist device for patients with Fontan physiology. The first approach
suggested the design of a noninvasive mechanical device which would augment Fontan
hemodynamics via external pressure application to the lower limbs and abdomen. This
thesis presented the results of a VCU IRB approved clinical trial for feasibility studies and
provided proof of concept for the design of a novel pressure garment. The pressure
garment is intended for patient use at home at their convenience to alleviate cardiac
workload providing hemodynamic relief. Results from patient trials indicate external
application to the lower limbs and abdomen of as little as 10 mmHg below baseline
diastolic may be enough to augment Fontan pressures and improve hemodynamics
functioning in a preventative and sustaining manner.
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The second approach involved the design of a minimally invasive, percutaneously
inserted, intravascular blood pump design for placement in the IVC. This collapsible axial
flow blood pump is designed with a 3-bladed impeller, 4-bladed diffuser, and radially
arranged cage filaments serving as touchdown surfaces to protect the vessel wall from
rotating components. This thesis presented the numerical analyses of the interactive fluid
dynamics between the cavopulmonary connection and a mechanical blood pump. The
pump would serve as a bridge-to-transplant, bridge-to-recovery, or bridge-to-surgical
reconstruction. A pressure augmentation of as little as 2 to 5 mmHg may be sufficient to
stabilize and reverse hemodynamic deterioration in Fontan patients. Computational
predictions indicate the blood pump would augment pressure acceptably in both the
idealized TCPC and patient specific TCPC models and result in a hydraulic energy boost
or gain for a range of viscosity values, LPA and RPA pressures, flow rates, and pump
rotational speeds. These results support the continued design and development of this
cavopulmonary assist device, building upon previous numerical work and future
experimental testing.
Both modalities that were evaluated in this thesis project showed tremendous
promise to potentially support Fontan patients in the acute and long-term clinical setting.
The designs of both modalities will evolve over time, ultimately leading to two viable
therapeutic options for Fontan patients and addressing a significant human health problem.
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APPENDIX A: MAST STUDY PROTOCOL
MAST Study Protocol:
1. After obtaining consent, place patient supine in MAST garment. MAST are not
inflated.
2. Place blood pressure cuff, pulse oximeter, standard ECG leads on patient. Insert
catheter according to VCU protocol for cardiac catherization.
3. Obtain and record baseline measurements onto data sheet. Based upon the patient’s
diastolic pressure, determine three pressure levels to evaluate:
1st Pressure level = (Diastolic BP) – 10 mmHg
2nd Pressure level = (Diastolic BP)
3rd Pressure level = (Diastolic BP) + 10 mmHg
4. Administer the first pressure level with the following procedure:
* Note: Clinical Measurements should be ongoing during this time.

Use pump to inflate MAST garment to 1st pressure level.
Hold pressure for 10 – 15 seconds.
Release pressure valve and deflate pants.
Hold deflated for 10 – 15 seconds.
Repeat cycle 5 times.
During the 5th cycle, reassess patient’s vital signs prior to
deflation.
7. Conclude after 5 minutes of Counterpulsation cycles.
8. Allow patient to rest for 3-5 minutes.
5. Administer the second pressure level with the following procedure:
1.
2.
3.
4.
5.
6.

* Note: Clinical Measurements should be ongoing during this time.

Use pump to inflate MAST garment to 1st pressure level.
Hold pressure for 10 – 15 seconds.
Release pressure valve and deflate pants.
Hold deflated for 10 – 15 seconds.
Repeat cycle 5 times.
During the 5th cycle, reassess patient’s vital signs prior to
deflation.
7. Conclude after 5 minutes of Counterpulsation cycles.
8. Allow patient to rest for 3-5 minutes.
6. Administer the third pressure level with the following procedure:
1.
2.
3.
4.
5.
6.

* Note: Clinical Measurements should be ongoing during this time.

1. Use pump to inflate MAST garment to 1st pressure level.
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2.
3.
4.
5.
6.

Hold pressure for 10 – 15 seconds.
Release pressure valve and deflate pants.
Hold deflated for 10 – 15 seconds.
Repeat cycle 5 times.
During the 5th cycle, reassess patient’s vital signs prior to
deflation.
7. Conclude after 5 minutes of Counterpulsation cycles.
8. Allow patient to rest for 3-5 minutes.
7. After the patient rests for 5 minutes, reevaluate baseline vital signs.
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APPENDIX B: RESEARCH SUBJECT CONSENT FORM

RESEARCH SUBJECT INFORMATION AND CONSENT FORM

TITLE OF RESEARCH: Clinical Measurement of Pressure Augmentation in the
Systemic Venous Circulation using Medical Anti-Shock Trousers

VCU IRB PROTOCOL NUMBER:

INVESTIGATORS:
Principal Investigator: Amy Throckmorton, Ph.D.
Sub/Co-Investigator: William B. Moskowitz, M.D.
Sub/Co-Investigator: Scott D. Gullquist, M.D.
Student: Sonya Bhavsar, B.S.
In ordinance with Federal Regulations for the Protection of Human Subjects section
§46.116, “An investigator shall seek…consent only under circumstances that provide the
prospective subject or the representative sufficient opportunity to consider whether or not
to participate and that minimize the possibility of coercion or undue influence.” After
carefully reading and understanding the information listed below, if you would like to
participate in this research study please sign this consent form indicating your
consent.
This consent form may contain words or information that you do not understand. Please
ask one of the investigators to explain any words or information that you do not
understand. You may take home an unsigned copy of this consent form to think about or
discuss with family or friends before making your decision.

PURPOSE OF THE RESEARCH STUDY:
The purpose of this research study is the test the effectiveness of routinely administered,
non-invasive, external couterpulsation therapy via Medical Anti-Shock Trousers (MAS
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trousers). MAS trousers are pants that have an air filled gap inside of them; they function
similar to blood pressure cuffs and can be inflated, only around the lower extremities or
legs, as opposed to the upper arm. We will have you slip on the pants and then, using air,
inflate these trousers. This will apply an external pressure to your legs in the form of light
compression. In doing so, we will measure how this externally applied pressure may
modify blood flow conditions in the circulation on the right side of your heart.
You are being invited participate in this study because you have been diagnosed with
single ventricle physiology or a closely related congenital heart defect and have already
scheduled to receive an evaluative cardiac catheterization. Therefore, we can perform this
study right before your cardiac catheterization in a safe and efficient manner.

WHAT YOU WILL DO IN THE STUDY:
Your participation in this study will last approximately 20 minutes per session. We will
acquire baseline vitals (blood pressure, heart rate, O2 saturation, respirations, right atrial
pressure/central venous pressure, and pulmonary capillary wedge pressure) prior to
inflating the pants with air, followed by three 3-5 minute sessions of incrementally
increasing inflation levels. Your vital signs will be monitored throughout the session and
again approximately 5 minutes after completion to obtain a second set of baseline vitals.
Sample Procedural Timeline:
1.) You will be placed in laying down, flat on your back. The MAS trousers will be
applied.
2.) We will apply a blood pressure cuff, pulse oximeter, and ECG leads. A catheter
will be inserted into your femoral vein after the site has been numbed with local
anesthetic.
3.) Your first set of vital signs will be obtained. We will determine the three
pressure intervals based upon your diastolic blood pressure.
4.) The first pressure level will be administered. The MAS trousers will inflate and
you will feel circumferential pressure applied to your lower extremities similar
to a blood pressure cuff.
5.) Your vital signs will be reassessed and the MAS trousers will deflate. You will
rest for 3-5 minutes.
6.) The second pressure level will be applied which is slightly higher than the
previous.
7.) Your vital signs will again be reassessed and the MAS trousers will deflate.
You will rest for 3-5 minutes.
8.) The third and final pressure level will be applied, your vital signs will be
assessed and the MAS trousers will deflate.
9.) After 5 minutes a second set of baseline vitals will be obtained.
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Your participation in this study will last approximately 20 minutes. Approximately 10
subjects will participate in this study.

RISKS AND RISK REDUCTION:
Prior to your enrollment in the study, an exclusion criteria was established to minimize any
potential risks. Because you have been invited to participate in this study, you were
determined to be at little to no risk.
Due to the short time period of external pressure application, there is minimal to no risk.
Deflation of the MAS trousers will be done methodically in order to maintain cardiac
stabilization. Your vital signs will be carefully monitored and adjustments will be made as
necessary.
You will also be carefully monitored for any sign or symptoms of shock, which will be
highly unlikely given the short duration (1-2 minutes) of externally applied pressure.
Significant concern would arise if the duration of applied pressure exceeded 20 minutes,
and the pressure was rapidly released, which will not occur during this study. Investigators
and a full clinical staff in the cardiac catheterization lab will be present to ensure that the
protocol will not be violated.
During the procedure, we will determine whether positive results are being observed. If the
observed results are not compliant with the hypothesized results, the procedure and study
will be immediately terminated.
All key personnel and resources normally found in the cardiac catheterization lab will be
present and attentive during the course of procedure.

BENEFITS TO YOU AND OTHERS:
There is no guarantee that you will receive any medical benefits from being in this study.
This is not a treatment study, and you may not receive any direct medical benefits from
your participation. The information from this research study may lead to better treatment in
the future for patients with single ventricle physiology or a closely related congenital heart
defect.
COMPENSATION:
No compensation will be provided for this study. The knowledge gained from this study
will be used to develop new MAS trousers or counterpulsation technology as a clinical
management tool for patients with single ventricle physiology or a closely related
congenital heart defect similar to yours.
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CONFIDENTIALITY
Adhering to IRB and Federal HIPPA regulations, only nonspecific information will be
recorded during this study. This information includes patient age, sex, and diagnosis.
Data being collected is for research purposes only. Your data will be identified by ID
numbers, NOT names, and stored separately from medical records in a secured spreadsheet
with the principle investigator.
Access to all data will be limited to study personnel. A data and safety monitoring plan is
established with accordance to IRB and Federal HIPPA regulations.

COMPENSATION FOR INJURY:
Virginia Commonwealth University and the VCU Health System have no plan for
providing long-term care or compensation in the event that you suffer injury as a result of
your participation in this research study.
If you are injured or if you become ill as a result of your participation in this study, contact
one of your investigators immediately. Your investigator will arrange for short-term
emergency care or referral if it is needed.
Fees for such treatment may be billed to you or to appropriate third party insurance. Your
health insurance company may or may not pay for treatment of injuries as a result of your
participation in this study.

VOLUNTARY PARTICIPATION AND WITHDRAWAL:
Your participation in this study is voluntary. If you decide to not participate in this study,
you will not suffer any penalty or loss of benefits to which you are otherwise entitled. If
you do participate, you are free to withdraw at any time. Your decision to withdraw will
involve no penalty or loss of benefits to which you are otherwise entitled.
Your principle investigator, co-investigators, or student investigator can stop your
involvement in the study at anytime without your consent. This could occur due to:
1.) The investigators believe it to be necessary for your health or safety
2.) You failed to comply with study instructions
3.) Administrative reasons requiring your withdrawal

QUESTIONS:
If you have any questions about this study, contact:
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Amy L. Throckmorton, Ph.D.
Assistant Professor
Department of Mechanical Engineering
Virginia Commonwealth University
VCU Box # 843015
Office (804)-827-2278
Fax (804)-827-7030
althrock@vcu.edu

William B. Moskowitz, M.D.
Professor, Pediatrics and Medicine
Interim Chair, Department of Pediatrics
Chairman, Division of Pediatric Cardiology
VCU/Medical College of Virginia
VCU Box #980646
Office (804)-828-9143
wmoskowitz@mcvh-vcu.edu

Scott D. Gullquist, M.D.
Associate Professor, Pediatric Cardiology
Department of Pediatrics
VCU/Medical College of Virginia
VCU Box #980646
Office (804)-828-5745
sgullquist@mcvh-vcu.edu
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Sonya Bhavsar, B.S.
Graduate Student Research Assistant
Department of Mechanical Engineering
Virginia Commonwealth University
Mobile (540)-915-1248
bhavsarss@vcu.edu

If you have questions about your rights as a research subject, you may contact:
Office of Research
Virginia Commonwealth University
800 East Leigh Street, Suite 113
PO Box 980568
Richmond, VA 23298
(804) 827-2157
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Do not sign this assent/consent form unless you have had a chance to ask questions
and have received satisfactory answers to all of your questions. Additional information
about participation in research studies can be found at:
http://www.research.vcu.edu/irb/volunteers.htm
ASSENT for a patient between the ages of 7 and 12
I agree to be in a study that uses MAS trousers (pants that inflate with air like a blood
pressure cuff) to determine changes in blood flow to the heart. This study was explained to
me by my parent/guardian and the doctor. They said that I could be in it. The only people
who will know about my results will be the people in charge of the study.
In this study I will put on a pair of pants that inflate with air like blood pressure cuffs. I
will be lying on my back. The doctor, nurses, and people in charge will be watching me
closely to make sure I am ok during the study. The pants will inflate and squeeze lightly on
both of my legs three times. It will only take about 20 minutes. If I ever feel
uncomfortable, I will tell the doctor and he will stop the study.
Writing my name below means that this page was read by me or to me and that I agree to
be in this study. I know what will happen to me during the study. If I decide to quit the
study, all I have to do is tell the person in charge.

__________________________________________
Child's Signature

__________________
Date

________________________________________
Name of Person Conducting Informed Assent

__________________________________________
Signature of Person Conducting Informed Assent

__________________
Date

__________________________________________
Signature of Investigator (if different from above)

__________________
Date
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ASSENT for a patient between the ages of 13 and 17
“I have read the description of the study titled Clinical Measurement of Pressure
Augmentation in the Systemic Venous Circulation using Medical Anti-Shock Trousers
which is printed above. I understand the procedures and what will happen to me in the
study. I have received permission from my parent(s) to participate in the study, and I agree
to participate in it. I know that I can quit the study at any time.”

________________________________
Signature of Child

____________________
Date

CONSENT
I have been provided with an opportunity to read this consent form carefully. All of the
questions that I wish to raise concerning this study have been answered.
By signing this consent form, I have not waived any of the legal rights or benefits, to
which I otherwise would be entitled. My signature indicates that I freely consent to
participate in this research study. I will receive a copy of the consent form once I have
agreed to participate.
Please read if you are the Parent/Legal Guardian of a patient participating in this study:
You are making the decision to allow your child to participate in this study. Your signature
below indicates that you have read the information provided above and have decided to
allow him or her to participate in this study. If your child is between the ages of 7 and 12,
your signature below indicates that you have talked with your child about the study and
believe he or she fully understands what will happen during the study. If you later decide
that you wish to withdraw your permission for your child to participate in the study, simply
tell an investigator or the doctor. You may discontinue his or her participation at any time.
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________________________________________________
Subject Name, printed

________________________________________________ ________________
Subject Signature
Date

_______________________________________________
Name of Parent or Legal Guardian
(Printed)

_______________________________________________ ________________
Parent or Legal Guardian Signature
Date

________________________________________________
Name of Person Conducting Informed Assent/Consent
Discussion / Witness
(Printed)
________________________________________________ ________________
Signature of Person Conducting Informed Assent/Consent
Date
Discussion / Witness

________________________________________________ ________________
Investigator Signature (if different from above)
Date
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